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 “MYOCARDIAL MAPPING IN EVALUATION OF MYOCARDIAL 
DISEASES AND ASSESSING NORMATIVE VALUES IN CONTROLS” 
 
1. INTRODUCTION 
 
The Extracellular Matrix (ECM) in a normal human heart is composed of 
collagen fibers, proteoglycans, glycosaminoglycans and fibroblasts. Myocardial 
fibrosis, defined as a significant increase in collagen volume fraction of myocardial 
tissue, is a common feature in various myocardial diseases 
[1]
. Myocardial fibrosis is a 
fundamental process in the development of myocardial dysfunction, leading to 
myocardial remodelling and poor outcomes 
[2–6].
 It is an independent risk factor for 
overall mortality.  
Several therapeutic strategies aimed at regression of interstitial fibrosis are 
available. Early identification of this underlying, often diffuse, interstitial myocardial 
fibrosis is thus important for diagnosis and essential for optimization of reversibility 
with intervention. 
Invasive cardiac imaging is a cornerstone of the diagnosis and it is extremely 
helpful in numerous cardiovascular pathologies. However, various myocardial 
diseases like cardiomyopathies, myocarditis, etc. are very difficult to diagnose.  
Until recently, myocardial fibrosis was not useful as a clinical marker because 
the only available method for assessment was invasive endomyocardial biopsy. 
However, this technique brings with it a risk of serious complications, is prone to 
sampling error and cannot detect the fibrotic involvement of whole ventricle, and was 
hence seldom performed.  
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As such a non-invasive whole-heart method of assessing myocardial fibrosis is 
required to distinguish fibrotic myocardium from normal myocardium. Multiple non-
invasive diagnostic strategies have been trialled for fibrosis assessment including: 
echocardiographic backscatter 
[7]
, nuclear imaging 
[8]
, peripheral collagen biomarkers 
[9]
 and molecular labelling techniques
 [10]
. Their clinical application has remained 
limited.  
 Cardiac imaging, especially cardiac magnetic resonance imaging (CMR), 
offers unique opportunities for detection and characterization of myocardial 
pathologies. It is noninvasive and allows accurate assessment of cardiac structure and 
function with detailed tissue characterisation and great level of accuracy and 
reproducibility 
[11].
 
Late gadolinium enhancement (LGE) imaging, also recognized as scar imaging 
is currently the primary tool for tissue characterization in CMR detecting focal 
myocardial fibrosis. Diffuse myocardial fibrosis is, however, more difficult to 
distinguish using LGE since the myocardial signal intensity may be nearly isointense 
and may be globally ―nulled‖ thus appearing to be normal tissue. LGE is 
contraindicated in renal dysfunction as it involves intravenous administration of 
gadolinium-based contrast agents. Moreover, LGE detects end-stage, irreversible 
tissue damage with replacement fibrosis. There is, therefore, a need for novel 
techniques that allow earlier detection of potentially reversible diffuse fibrosis, 
frequently missed using LGE.  
Such early tissue characterisation can be achieved using MRI techniques that 
allow direct quantification of signal from the myocardium via parametric mapping 
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techniques - T1 and T2 mapping. All tissues have natural tissue-specific longitudinal 
(T1) and transverse (T2) relaxation times. These may be altered in disease. Mapping 
techniques measure these and display the actual values in colour on a pixel-by-pixel 
basis for regional, and between-patient, comparisons without the need for post-
processing. Thus, mapping can noninvasively represent a "sample" of tissue from the 
entire myocardium and supplement or potentially replace invasive myocardial biopsy 
[12]. Further, it may help identify the most appropriate location for biopsy, if biopsy is 
deemed clinically necessary. 
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2. RATIONALE OF THE STUDY 
 
Cardiac-MRI has been established as the reference standard for the evaluation 
of cardiac anatomy and function. Late-gadolinium-enhancement also allows 
myocardial characterization, although the technique possesses limitations in diffuse 
myocardial fibrosis. In this setting T1 mapping emerges as a promising tool.  
Cardiac MR imaging has relied primarily on a qualitative characterization of the 
myocardium through visual analysis of characteristic enhancement patterns on late 
gadolinium-enhanced (LGE) MR images. By using a T1-weighted inversion recovery 
sequence (to null normal myocardium), after gadolinium administration, the signal 
difference between normal myocardium and focal fibrosis can be identified. Areas of 
fibrosis demonstrate greater gadolinium accumulation which is represented as a region 
of high intensity signal with a shorter T1 time than adjacent normal tissue. 
Traditional LGE MR images have two main limitations: 
1. The identification and characterization of enhancement patterns is 
subjective, being susceptible to inter- and intraobserver variations. 
2. Diffuse fibrosis may go undetected, as normal myocardium is needed as a 
standard of reference to contrast with a pattern of enhancement. 
To surpass these limitations, new tissue characterization strategies have been 
proposed, including the so-called T1 mapping technique
 [13]
. 
The native T1 measurement of myocardium can also detect important 
pathophysiologic processes, related to excess of water as in oedema 
[14,15]
, protein 
deposition 
[16, 17],
 and otherT1-altering substances, such as lipid 
[18, 19]
 or 
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iron(haemorrhage, siderosis) 
[20]
, without the use of gadolinium, and therefore it can 
also be applied in patients with severe renal failure. Changes of myocardial native T1 
mapping reflect cardiac diseases, such as acute coronary syndromes, infarction, 
myocarditis, and diffuse fibrosis (that present with high T1) 
[21]
, and systemic 
diseases, such as cardiac amyloid (high T1) 
[21]
 Anderson-Fabry disease (low T1) 
[22]
, 
and siderosis (low T1).  
The T2 mapping technique can accurately and reliably detect areas of 
myocardial oedema without the limitations of qualitative T2W imaging namely (a) 
signal intensity variability caused by phased array coils, (b) high signal from slow-
moving ventricular blood that can mimic and mask elevated T2 in subendocardium,(c) 
motion artefacts, and (d) the subjective nature of T2W image interpretation. 
T2 mapping sequences are useful for the detection of myocardial oedema due 
to acute myocardial infarction 
[23]
, myocarditis 
[24, 25], 
stress cardiomyopathy 
[24, 26]
 , 
sarcoidosis 
[27]
 , and cardiac allograft rejection 
[28]
 . T2 mapping is considered superior 
compared with standard CMR parameters, global myocardial T1 mapping, and ECV 
for assessing the activity of myocarditis inpatients with recent-onset heart failure and 
reduced left ventricular function 
[29]
. Furthermore, T2 mapping was proven to be a 
novel non-invasive tool or transplant monitoring, and in rejection detection 
[30]
. 
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3. ANATOMY AND REVIEW OF LITERATURE 
 
CARDIAC EMBRYOLOGY 
 
ESTABLISHMENT OF THE CARDIOGENIC FIELD 
The vascular system appears in the middle of the third week. Cardiac 
progenitor cells lie in the epiblast, immediately lateral to the primitive streak. From 
there, they migrate through the streak rostral to the oropharyngeal membrane and 
neural folds in the splanchnic layer of the lateral plate mesoderm. They are induced by 
the underlying pharyngeal endoderm to form cardiac myoblasts. Blood islands also 
appear in this mesoderm, where they will form blood cells and vessels. With time, the 
islands unite and form a horseshoe-shaped endothelial-lined tube surrounded by 
myoblasts. This region is known as the cardiogenic field; the intraembryonic cavity 
over it later develops into the pericardial cavity. 
FORMATION AND POSITION OF THE HEART TUBE 
Initially, the cardiogenic area is anterior to the oropharyngeal membrane and 
the neural plate. With closure of the neural tube and formation of the brain vesicles, 
the central nervous system grows cephalad and extends over the central cardiogenic 
area. As a result of growth of the brain and cephalic folding of the embryo, the heart 
and pericardial cavity move to the thorax. 
As the embryo folds cephalocaudally, it also folds laterally. As a result, the 
caudal regions of the paired cardiac primordia merge except at their caudal most ends. 
Thus, the heart becomes a continuous expanded tube consisting of an inner endothelial 
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lining and an outer myocardial layer. It receives venous drainage at its caudal pole and 
begins to pump blood out of the first aortic arch into the dorsal aorta at its cranial pole. 
 
Fig 3.1 Effects of the rapid growth of the brain on positioning of the heart 
During these events, the myocardium thickens and secretes a thick layer of 
extracellular matrix, rich in hyaluronic acid that separates it from the endothelium. 
Mesothelial cells on the surface of the septum transversum form the proepicardium 
near the sinus venous and migrate over the heart to form most of the epicardium. 
Thus, the heart tube consists of three layers: (a) the endocardium, forming the internal 
endothelial lining of the heart; (b) the myocardium, forming the muscular wall; and (c) 
the epicardium or visceral pericardium, covering the outside of the tube.  
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FORMATION OF THE CARDIAC LOOP 
The heart tube continues to elongate and bend on day 23. The cephalic portion of the 
tube bends ventrally, caudally, and to the right; and the atrial (caudal) portion shifts 
dorsocranially and to the left. This bending creates the cardiac loop. It is complete by 
day 28. The atrial portion, initially paired, forms a common atrium. The 
atrioventricular junction remains narrow and forms the atrioventricular canal. The 
bulbus cordis is narrow except for its proximal third, which forms the trabeculated 
part of the right ventricle. The midportion, the conus cordis forms the outflow tracts of 
both ventricles. The distal part of the bulbus, the truncus arteriosus forms the roots and 
proximal portion of the aorta and pulmonary artery. The junction between the 
ventricle and the bulbus cordis, remains narrow and is called the primary 
interventricular foramen.  
 
Fig 3.2 Formation of the cardiac loop 
 
At the end of loop formation, the smooth walled heart tube begins to form 
primitive trabeculae just proximal and distal to the primary interventricular foramen. 
The primitive ventricle, which is now trabeculated, is called the primitive left 
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ventricle. The trabeculated proximal third of the bulbus cordis is called the primitive 
right ventricle. 
DEVELOPMENT OF THE SINUS VENOSUS 
In the middle of the fourth week, the sinus venosus receives venous blood from 
the right and left sinus horns. Each horn receives blood from three important veins: (a) 
the vitelline or omphalomesenteric vein, (b) the umbilical vein, and (c) the common 
cardinal vein. At first, communication between the sinus and the atrium is wide. Soon, 
the entrance of the sinus shifts to the right during the fourth and fifth weeks of 
development. 
With obliteration of the right umbilical vein left vitelline vein, left common 
cardinal vein and the left sinus horn rapidly loses its importance and all that remains is 
the oblique vein of the left atrium and the coronary sinus. 
 
Fig 3.3 Dorsal view of two stages in the development of the sinus venosus at 
approximately 24 days (A) and 35 days (B). ACV, anterior cardinal vein; PCV, 
posterior cardinal vein; UV, umbilical vein; VIT V, vitelline vein; CCV, common 
cardinal vein. 
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FORMATION OF THE CARDIAC SEPTA 
Septum Formation in the Common Atrium 
At the end of the fourth week, a sickle-shaped crest grows from the roof of the 
common atrium into the lumen. This crest is the first portion of the septum primum. 
The septum extend toward the endocardial cushions in the atrioventricular canal. The 
opening between the lower rim of the septum primum and the endocardial cushions is 
the ostium primum. Extensions of the endocardial cushions grow along the edge of the 
septum primum, closing the ostium primum. Before closure is complete, perforations 
form in the upper portion of the septum primum which coalesce to form the ostium 
secundum. 
A crescent-shaped fold appears the lumen of the right atrium called the septum 
secundum which extends downward to the septum in the atrioventricular canal. The 
free concave edge of the septum secundum overlaps the ostium secundum. The 
opening left by the septum secundum is called the oval foramen (foramen ovale). The 
passage between the two atrial cavities consists of an obliquely elongated cleft 
through which blood from the right atrium flows to the left side. After birth, when 
lung circulation begins and pressure in the left atrium increases, the valve of the oval 
foramen is pressed against the septum secundum, obliterating the oval foramen and 
separating the right and left atria.  
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Fig 3.4 Atrial septa at various stages of development 
Further Differentiation of the Atria  
The primitive right atrium enlarges by incorporation of the right sinus horn. 
Initially, a single embryonic pulmonary vein develops as an outgrowth of the posterior 
left atrial wall. This vein gains connection with veins of the developing lung buds. 
Ultimately, four pulmonary veins are incorporated into the left atrium, forming its 
smooth walled part. In the fully developed heart, the embryonic left atrium is 
represented by the trabeculated atrial appendage, while the smooth-walled part 
originates from the pulmonary veins. The embryonic right atrium becomes the 
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trabeculated right atrial appendage and the smooth-walled sinus venarum originates 
from the right horn of the sinus venosus. 
 
Fig 3.5 Development of the smooth-walled portions of the right and left atriu.  
 
Septum Formation in the Atrioventricular Canal 
At the end of the fourth week, two mesenchymal atrioventricular endocardial 
cushions, appear at the anterior and posterior borders of the atrioventricular canal. In 
addition to these, the two lateral atrioventricular cushions appear on the right and left 
borders of the canal. The anterior and posterior cushions, project further into the 
lumen and fuse, resulting in a complete division of the canal into right and left 
atrioventricular orifices by the end of the fifth week. 
 
Fig 3.6 Formation of the septum in the atrioventricular canal 
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Septum Formation in the Truncus Arteriosus and Conus Cordis 
During the fifth week, pairs of opposing ridges appear in the truncus, the 
truncus swellings, or cushions. While growing toward the aortic sac, the swellings 
twist around each other in a spiral course. After complete fusion, the ridges form the 
aorticopulmonary septum, dividing the truncus into an aortic and a pulmonary 
channel. 
Similar swellings (cushions) develop along the walls of the conus cordis which 
grow toward each other and unite with the truncus septum. When the two conus 
swellings have fused, the septum divides the conus into an anterolateral portion (the 
outflow tract of the right ventricle) and a posteromedial portion (the outflow tract of 
the left ventricle). 
 
Fig 3.7 Development of the conotruncal ridges (cushions) and closure of the 
interventricular foramen. 
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Septum Formation in the Ventricles 
By the end of the fourth week, the two primitive ventricles begin to expand. 
This is accomplished by continuous growth of the myocardium on the outside and 
continuous diverticulation and trabecula formation on the inside. The medial walls of 
the expanding ventricles become apposed and gradually merge, forming the muscular 
interventricular septum. The space between the free rim of the muscular ventricular 
septum and the fused endocardial cushions permits communication between the two 
ventricles. It is closed by outgrowth of tissue from the inferior endocardial cushion 
along the top of the muscular interventricular septum. Complete closure of the 
interventricular foramen forms the membranous part of the interventricular septum
 [31]
. 
 
CARDIAC ANATOMY 
The major cardiac structures that can be identified on MRI are: 
RIGHT ATRIUM 
The morphologic right atrium is derived from the right atrial appendage and 
sinus venosus 
[32]
. The sinus venosus has a smooth wall and receives the inferior vena 
cava and superior vena cava–coronary sinus, and the right atrial appendage is 
triangular-shaped with a wide opening and contains rough trabeculations or pectinate 
muscles. These two components of the right atrium are separated by the crista 
terminalis (terminal crest). The crista terminalis is readily visualized on both bright 
and dark blood sequences and appears isointense to the myocardium. A prominent 
crista terminalis can mimic a mass. However, the location and signal characteristics on 
MRI can help confirm that this structure is indeed normal cardiac tissue 
[33]
. The 
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valves of the coronary sinus (thebesian valve) and inferior vena cava (Eustachian 
valve) are also readily apparent on MRI.  
RIGHT VENTRICLE 
The right ventricle receives blood from the right atrium and consists of inlet, 
outlet, and apical portions 
[32]
.The inlet contains the tricuspid valves and associated 
chordal attachments. Attachment of the chords to the septum is characteristic of the 
tricuspid valve. The apical portion of the right ventricle is trabeculated, whereas the 
outlet is smooth and leads to the pulmonary artery. The right ventricle also contains 
the moderator band, which courses from the apical portion at the anterior papillary 
muscle insertion to the interventricular septum. 
LEFT ATRIUM 
The left atrium is the most posterior and superior chamber and receives 
pulmonary venous return 
[32]
. The left atrium is also attached to the left atrial 
appendage, which is more elongated and narrower than the right atrial appendage. The 
left atrium is smaller and contains fewer trabeculations than the right atrium. The 
interatrial septum separates the right and left atria and features the fossa ovalis, which 
appears as an area of focal thinning. 
LEFT VENTRICLE 
The left ventricle comprises inlet, apical, and outlet segments and is separated 
from the right ventricle by the interventricular septum 
[32]
. The septum normally 
bulges toward the right ventricle. Consequently, on short-axis views, the left ventricle 
has a rounded profile. The left ventricle inlet and outlet are continuous with one 
another and include the mitral and aortic valves, respectively. The apical region of the 
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left ventricle contains the two papillary muscles, which are larger than those in the 
right ventricle. In adults, the lateral wall of the normal left ventricle should 
measureless than 1 cm in thickness 
[34]
.  
CORONARY ARTERIES 
The coronary arteries arise from the aortic sinuses, just distal to the aortic 
valve. The right coronary artery (RCA) courses along the atrioventricular groove and 
is dominant in approximately 85% of individuals, giving rise to the posterior 
descending artery (PDA), which courses along the posterior interventricular sulcus 
toward the apex. The RCA also supplies the conal branch, right marginal branches, 
posterolateral ventricular branch, and frequently the sinus node artery. The left main 
coronary artery is a short trunk that supplies the left anterior descending (LAD) and 
left circumflex arteries. In up to 30% of individuals an additional ramus intermedius 
artery arises from the bifurcation of the left main coronary artery 
[32]
. The LAD 
courses along the anterior interventricular sulcus and give rise to the diagonal and 
septal branches. The left circumflex artery supplies the obtuse marginal branches and 
sometimes supplies the sinus node artery and PDA in a left-dominant or codominant 
system.  
 17 
 
Fig 3.8 Normal cardiac MRI anatomy. Short-axis (A), horizontal long-axis (B) 
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Fig 3.8 Normal cardiac MRI anatomy. Two-chamber (C), right ventricular 
outflow tract (D), and left ventricular outflow tract (E) views. 
Ao = aorta, AIVG = anterior interventricular groove, APM = anterior papillary 
muscle, AV = aortic valve, CS = coronary sinus, CT = crista terminalis, D = 
diaphragm, EV = eustachian valve, FO = fossa ovalis, IAS = interatrial septum, IVC = 
inferior vena cava, IVS = interventricular septum, LA = left atrium, LAAP = left atrial 
appendage, LAD = left anterior descending artery, LCA = left coronary artery, LCCA 
= left common carotid artery, LCX = left circumflex artery, LIV = left innominate 
vein, LMB = left mainstem bronchus, LPA = left pulmonary artery, LV = left 
ventricle, LVOT = left ventricular outflow tract, MB = moderator band, MV = mitral 
valve, PA = pulmonary artery, PMVL = posterior mitral valve leaflet, PPM = 
posterior papillary muscle, PUV = pulmonary valve, RA = right atrium, RAAP = right 
atrial appendage, RCA = right coronary artery, RMB = right mainstem bronchus, RPA 
= right pulmonary artery, RV = right ventricle, RVOT = right ventricular outflow 
tract, SVC = superior vena cava, T = trachea, TV = tricuspid valve, PV = pulmonary 
vein. 
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REVIEW OF LITERATURE 
MYOCARDIAL DISEASES 
 
Cardiac extracellular matrix (ECM) is a complex mesh-work of fibers 
comprised of matrix proteins in which cardiac myocytes, fibroblasts, leukocytes, and 
blood vessels reside. It plays an important role in the maintenance of ventricular 
shape, size and function. In the normal human heart, it is predominantly made up of 
collagen types I (80%) and III (11%). 
Myocardial fibrosis results from a significant increase in the collagen volume 
fraction of myocardial tissue (> 25%). The distribution of myocardial fibrosis varies 
according to the underlying pathology and is always present in end-stage heart failure. 
According to the cardiomyopathic process three different types of myocardial fibrosis 
have been described: 
1. Reactive interstitial fibrosis 
Reactive fibrosis refers to increased ECM deposition due to direct stimulation 
of fibroblasts without cell injury. It has a progressive onset and a diffuse distribution. 
This type of fibrosis is present in hypertension and diabetes mellitus, aging heart, 
idiopathic dilated cardiomyopathy, and in left ventricular pressure- overload and 
volume-overload states induced by valvular disease. 
2. Infiltrative interstitial fibrosis 
This subtype of fibrosis is induced by progressive deposit of insoluble proteins 
(amyloidosis) or glycosphingolipids (Anderson-Fabry disease) in the cardiac 
interstitium. 
3. Replacement fibrosis 
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Replacement or reparative fibrosis refers to ECM deposition during scar 
formation as a result of tissue injury or cell death. 
It can have a localized distribution (ischaemic cardiomyopathy, myocarditis, 
hypertrophic cardiomyopathy, and sarcoidosis) or a diffuse distribution (chronic renal 
insufficiency, toxic cardiomyopathies, inflammatory disease). 
Reactive interstitial fibrosis and infiltrative fibrosis ultimately lead to 
replacement fibrosis in the later stages of disease, where cellular damage and 
cardiomyocyte necrosis/apoptosis appear
 [13]
. 
HYPERTROPHIC CARDIOMYOPATHY 
Hypertrophic cardiomyopathy (HCM) is the most common inheritable cardiac 
disorder, which is characterized by abnormal thickening of the left ventricular 
myocardium. The heart of a patient with archetypal HCM has an asymmetric or a 
symmetric increase in left ventricular wall thickness with a left ventricular cavity 
which is reduced in size. There is a broad range of phenotypic expressions with 
asymmetric involvement of the interventricular septum being the most common 
pattern. A high proportion of cases are now recognised to be caused by mutations in 
genes coding for myofibrillary proteins 
[35]
. Most of the clinical manifestations of the 
disease involve either diastolic or systolic dysfunction, left ventricular outflow tract 
(LVOT) obstruction, arrhythmias and sudden cardiac death. 
 
DILATED CARDIOMYOPATHY 
The term dilated cardiomyopathy (DCM) is applied in the presence of left 
ventricular or biventricular dilatation and dysfunction following systematic exclusion 
of all obvious or detectable causes of cardiomyopathy. Common to the whole group is 
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a poorly contracting dilated left ventricle with a normal or reduced left ventricular 
wall thickness. The lack of an increase in left ventricular wall thickness tends to mask 
a significant increase in left ventricular mass. In the terminal stages thrombus may 
develop in the apices of both ventricles. In up to 50% of cases the etiology remains 
unknown. Many of the rest can be traced to previous infection, alcohol or drug abuse, 
or drug toxicity. 
[36, 37] 
RESTRICTIVE CARDIOMYOPATHY 
Restrictive cardiomyopathy (RCM), in which the left ventricle is nearly normal 
in shape but there is a failure of the myocardium to relax in diastole, is one form of 
cardiomyopathy where cardiac biopsy may help. The most common form is 
myocardial amyloid. It is usually easy to recognise amyloid on histology by its 
characteristic green colour under polarised light after staining with Sirius red dye. 
Other causes of restriction include diffuse perimyocyte fibrosis. This pattern of 
fibrosis is seen to a degree in many cases of DCM, but when in a uniform distribution 
it appears to cause predominant restriction. The pathogenesis of this form is unknown. 
Another form of RCM is familial and associated with myocyte disarray on biopsy, but 
without other clinical or morphological features of HCM. The gene(s) responsible 
have not yet been identified
 [35]
. 
 
AMYLOIDOSIS 
Cardiac amyloidosis is an interstitial deposition of amyloid fibrils that causes 
concentric thickening of the atrial and ventricular walls, where it leads to secondary 
restrictive cardiomyopathy. Amyloid is not, however, evenly distributed in the 
ventricle and false negatives occur. Some cases develop a florid myocardial fibrotic 
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response masking the amyloid. There are three main types of primary amyloidosis: 
light chain (AL) amyloidosis, senile systemic amyloidosis and hereditary amyloidosis 
(mutant form of transthyretin). Cardiac involvement is an important prognostic factor 
of this disease
 [13]
.  
MYOCARDITIS 
Myocarditis is an acute or chronic inflammatory disease of the myocardium 
which can be viral, postinfectious immune or primarily organ-specific autoimmune. 
The diagnosis of myocarditis is a challenging process, because of its diverse 
presentation, overlapping symptoms and limited sensitivity of endomyocardial 
biopsies 
[38]
. The clinical picture of acute myocarditis is characterised by the rapid 
onset of cardiac failure or arrhythmias, or both, with fever, malaise, myalgia, and 
sometimes pericarditis. It has a morphological counterpart (Dallas criteria)
[39]
 of 
myocyte necrosis, usually in a multifocal but sometimes regional distribution, with a 
heavy interstitial infiltrate of T lymphocytes. The reported positivity rate of 
myocardial biopsy varies is usually no more than 10%. The biopsy negative but 
clinically positive cases create a diagnostic challenge and are likely to be 
heterogeneous in origin. Some may be genuine cases of myocarditis, but the biopsy is 
taken after the T lymphocyte infiltrate has cleared. Other cases may reflect the 
limitations of cardiac biopsy because with a focal disease the sample taken may come 
from an area of normal myocardium. Early diagnosis is mandatory to address specific 
directed therapeutic management that influences patient morbidity and mortality. 
The major cause of acute myocarditis is perceived to be viral, involving in 
particular the coxsackie group of viruses. Viruses other than those from the coxsackie 
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group like the adeno group. A very wide range of viruses such as those responsible for 
chicken pox, measles, rubella, and mumps often cause a minor degree myocarditis. A 
small subgroup of myocarditis may be caused by non-viral organisms, such as the 
spirochaete Borrelia burgdorferi in Lyme disease, toxoplasma, and leptospira, while in 
South America Trypanosoma cruzi is by far the most common cause of the acute 
myocarditis of Chagas‘ disease. Patients with biopsy positive or negative myocarditis 
may die in the acute phase or recover. Recovery is usually complete although there are 
a few reported cases of slow progression into DCM. The Dallas criteria for acute 
myocarditis on cardiac biopsy defined the need for severe myocyte damage plus a T 
lymphocyte interstitial inflammatory cell infiltrate
 [35]
.  
 
MYOCARDIAL INFARCTION 
Myocardial infarction (MI) is defined as myocardial cell death secondary to 
prolonged ischemia that results in an inadequate supply of oxygenated blood to an 
area of the myocardium, particularly when ischemia exceeds a critical threshold that 
overwhelms cellular repair mechanisms. MI is typically caused by luminal thrombosis 
superimposed on coronary atherosclerosis. Occasionally, it can be caused by coronary 
spasm, coronary embolism, or thrombosis in nonatherosclerotic vessels. Arteritis, 
dissection, congenital abnormalities, hypercoagulable states, and cocaine use are 
uncommon causes.  
MI is the leading cause of death and a main cause of morbidity worldwide. In 
these patients, MI may present as a major catastrophic event, such as sudden cardiac 
death, or as a minor event in a chronic disease; MI may also remain silent. MI is most 
 24 
commonly observed in patients aged 40–65 years and are more typically severe or 
lethal in women 
[39]
.  
In MI, biochemical and functional abnormalities begin immediately after the 
onset of ischemia; loss of contractility occurs in 60 seconds and loss of viability 
occurs in 20–40 minutes. The changes progress from the initial decrease in perfusion, 
leading to diminished tissue oxygenation, decreased phosphocreatine, repolarization 
abnormalities, diastolic dysfunction, systolic dysfunction, decreased adenosine 
triphosphate, edema, and finally tissue necrosis. The infarct progresses like a ―wave 
front‖ from the endocardium to the epicardium. Complete necrosis takes 2–4 hours or 
longer, depending on the presence of collateral circulation, persistent or intermittent 
coronary arterial occlusion, sensitivity of myocytes to ischemia, preconditioning, and 
individual demand for myocardial oxygen and nutrients.  
An infarct is termed microscopic when <10% of the myocardium is involved, 
moderate when 10%–30% is involved, and large when >30% is involved [40]. 
Transmural MI affects the full thickness of affected muscle segments, from endocar-
dium through midmyocardium to epicardium; nontransmural MI does not extend 
through the full thickness of the myocardial segments and is limited to endocardium 
or to endocardium plus midmyocardium. Clinically, MI can occur as either ST-
segment elevation MI (STEMI) or non–ST-segment elevation MI (NSTEMI) [41].  
ARRHTMMOGENIC RIGHT VENTRICULAR DYSPLASIA 
             Arrhythmogenic right ventricular dysplasia (ARVD) is characterised by areas 
in the right ventricle where there is transmural replacement of the myocytes largely by 
adipose tissue, but with some fibrosis leading to focal areas of aneurysmal dilatation. 
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The first cases recognised were first recognised in young subjects with normal 
exercise tolerance who died suddenly at the extreme end of the spectrum, but family 
studies and wider clinical studies using magnetic resonance imaging in subjects with 
unexplained ventricular tachycardia revealed that the areas of abnormality may be 
small—no more than 1–2 cm across. About a third of cases have concomitant left 
ventricular involvement with fibrofatty replacement of myocytes, often subpericardial 
and maximal on the posterior wall. In most but not all cases the myocardial 
involvement, while acting as a substrate for arrhythmias, does not significantly reduce 
right or left ventricular contractile function. 
In patients with a known family history or with clear ECG and echocardiographic 
changes suggesting ARVD, cardiac biopsy is a useful confirmatory investigation but 
is rarely diagnostic in its own right. The focal nature of the disease means false 
negatives are common, while simple adipose infiltration into the right ventricular 
myocardium without replacement of myocytes or fibrosis is a common finding in 
normal subjects, particular women. Biopsy findings of fat in the right ventricular wall 
can be over interpreted and lead to false positives. The diagnosis of ARVD has to be 
based on the concordance of clinical and pathological features. 
ARVD is genetic and several sites of candidate genes have been identified on different 
chromosomes. At present what these genes control or produce is unknown. The 
histological changes are different from those in DCM because although myocytes are 
being lost in both conditions, in ARVD there is a predominant replacement by adipose 
tissue. In many cases of ARVD there is an inflammatory cell infiltrate in the abnormal 
areas of myocardium. This has been interpreted as a myocarditic component but could 
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be a secondary rather than a primary change. The frequency of ARVD is impossible to 
establish accurately at present because the less striking cases are underdiagnosed both 
in life and after death 
[13, 35]
.  
IMAGING OF MYOCARDIAL DISEASES 
ECHOCARDIOGRAPHY 
Echocardiography is one among the imaging modalities for diagnostic 
evaluation, follow-up and analysis of treatment results of myocardial pathologies. It is 
an accessible, inexpensive and reproducible first-line modality for the assessment of 
ventricular size and function. The current ultrasound equipments exhibit an impressive 
improvement of heart image resolution and Doppler effect sensibility. New resources 
such as tissue Doppler, motivate the development of more studies, whose results are 
already adding themselves to the current resources on the prognostic and diagnostic 
evaluation of myocardial diseases. However, echocardiography requires suitable 
imaging windows and provides limited capability for tissue characterization
 [43]
. 
Dilated cardiomyopathy 
2D echocardiographic findings characteristically show left ventricular (LV) 
dilatation (with variable involvement of the right ventricle and to a lesser degree the 
atria), poor systolic myocardial thickening and reduced systolic indices (i.e. LVEF < 
50%).Additional features may include mitral or aortic valve incompetence
 [44]
.  
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Fig 3.9 Dilated cardiomyopathy - Four chamber echocardiogram showing left 
ventricular dilatation 
 
Hypertrophic cardiomyopathy 
 
Echocardiography shows LV hypertrophy typically involving the 
interventricular septum. However, any diffuse or segmental pattern of LV wall 
thickening is possible. Diagnostic criterion is a maximal LV wall thickness greater 
than or equal to 15 mm in the end-diastolic phase (normal range ≤12 mm) [45]. 
Variation of myocardial hypertrophy may include asymmetric or non-contiguous 
myocardial involvement. Right ventricular (RV) muscular hypertrophy (17%) 
[46]
 may 
also be seen, most commonly involving the mid to apical portion of the right ventricle. 
Restrictive cardiomyopathy 
Echocardiography usually demonstrates normal LV cavity size and systolic 
function, biatrial enlargement, with abnormal diastolic function. Furthermore, in 
restrictive cardiomyopathy, pulmonary venous systolic flow is reduced with a 
consequent rise in diastolic flow. This can be utilized to exclude constrictive 
pericarditis. The measurement of transmitral peak flow velocity in early diastole (E) 
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and during atrial contraction (A), the E/A ratio, is another useful parameter that can be 
measured via echocardiography 
[46]
. In diastolic dysfunction, due to reduced 
ventricular compliance, a greater percentage of end diastolic volume results from late 
rather than early filling because of the stiffness of the ventricle. Therefore E/A ratio is 
reduced. 
 
Fig 3.10 Echocardiography four chamber view showing bi-atrial enlargement in 
restrictive cardiomyopathy 
 
Arrhythmogenic right ventricular dysplasia 
Echocardiographic investigation is limited in ARVD because much of the right 
ventricular free wall lies posterior to the sternum and ribs. Furthermore, it is not useful 
at demonstrating intramyocardial fat. Echocardiography can demonstrate a 
hypokinetic and dilated right ventricle. A right ventricular outflow tract (RVOT) 
dimension >30 mm from the parasternal long-axis view has a sensitivity (89%) and 
specificity (86%) for the diagnosis of ARVD 
[47]
. 
 
COMPUTED TOMOGRAPHY 
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Computed tomography (CT) achieves excellent tissue characterization, with 
high spatial resolution in short acquisition times. It excels at cross-sectional, 
anatomical imaging and has developed as the gold standard for non-invasive 
angiography. Although less widely utilized for functional analysis, its ability to 
accurately assess left ventricular (LV) function has been known for many years 
[48]
, 
and it is recommended for such where other methods are unsuitable, and to evaluate 
right ventricular (RV) morphology and function
 [49]
. Cardiac CT is increasingly 
relevant to every subspecialty of cardiology. Guidance for revascularization, 
aetiological diagnosis in heart failure, identification of potentially arrhythmogenic 
scar, and assessment of complex congenital heart disease are achievable. 
While the gold standard modalities for such assessment are cardiac magnetic 
resonance and echocardiography, these are not universally suitable. Cardiac computed 
tomography (CT), well-established for the assessment of coronary artery disease 
(CAD), can be of value in the assessment of myocardial pathology, due to excellent 
patient compatibility and tolerability, high spatial resolution, and acceptable tissue 
characterization. 
CT is not without limitations and image quality can be impaired by both patient 
and acquisition factors, including excessive cardiac motion, or respiration
[50]
, although 
myocardial CT requires less meticulous patient preparation than for coronary analysis, 
with less restrictive target heart rates. Errors peculiar to CT can occur, such as beam-
hardening artefact, due to the disproportionate attenuation of lower energy photons in 
the X-ray beam by highly dense structures, such as calcium or contrast. This is 
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particularly problematic where the volume of contrast in the ventricles causes 
‗shadowing‘ over the myocardium, limiting evaluation, or mimicking pathology. 
The inescapable limitation of CT has been radiation dose, although this has 
fallen considerably in recent years
 [51]
 due to improved methods of acquisition, patient-
specific scanning protocols, and novel image reconstruction methods. The latest 
reconstruction techniques offer potential for even greater dose reductions. Ultra-low-
dose techniques can produce some thoracic CT images for as little radiation as a chest 
radiograph
 [52]
. 
The assessment of myocardial structure and function is perhaps most 
comprehensive using retrospective electrocardiographic (ECG) gating, where images 
are taken throughout a number of cardiac cycles and diagnostic data then 
retrospectively extracted. This method provides data from entire cycles, permitting 
visualization of dynamic function but requiring longer, multi-cycle exposure to the X-
ray beam and thus a higher radiation dose. This has led to the development of 
prospective techniques, where the X-ray tube is ‗on‘ for only the portions of the 
cardiac cycle required for diagnosis; typically for coronary assessment this in mid-
diastole or end-systole. Functional information is less readily available with this 
method.  
Contrast timing is also important to consider, particularly when a CT is being 
used for the assessment of cardiac structure rather than for solely coronary analysis. If 
both LV and RV analyses are required, the scan must be undertaken using either a 
larger volume of contrast, or a slower rate (or both) to ensure that the right-sided 
cardiac chambers remain opacified during left-sided filling. Conversely, if shunts are 
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suspected then it is important to maintain a contrast differential, so that aberrant blood 
flow can be clearly demonstrated. When retrospective techniques are still employed, 
the assessment of myocardial function, including ejection fraction and identification 
of regional wall motion abnormalities, approaches the accuracy of cardiac magnetic 
resonance imaging (MRI) 
[53]
. It is concordant with, and potentially superior to, two-
dimensional echocardiography, with greater accuracy and reproducibility
 [54]
.Such data 
can be rapidly generated using the semi-automated software to identify the coronary 
phases, delineate the blood volumes, and calculate chamber sizes and ejection 
fractions. 
As with echo, CT can offer morphological screening, particularly in patients 
with concomitant cardiomyopathy and coronary artery disease (CAD). Chamber 
dimensions and wall thickness can be precisely measured, and dilated or hypertrophic 
cardiomyopathies (HCMs) identified
 [55]
. This must be performed diligently as wall 
thickness and chamber size require precise measurements, usually in end-diastole.  
Other structural pathology is less reliant on accurate timing and with the 
exception of wall thickness and function, a single-phase examination is usually 
sufficient. LV non-compaction is readily identifiable on cardiac CT
 [56]
, and 
assessment for LV thrombus can be reliably undertaken. Chamber and conduit 
identification can also be easily conducted for patients with congenital heart disease, 
while identifying lesions such as shunts and anomalous coronary arteries (Figure 2C), 
which may be contributing to myocardial abnormality
[57]
. In this manner, CT is useful 
for identifying additional features associated with particular myocardial pathologies.  
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Ischaemic cardiomyopathy 
The assessment of CAD remains the major application for cardiac CT
 [49]
. CT is 
commonly used to rule out ischaemia as a cause of cardiomyopathy 
[58]
. The co-
localization of coronary artery calcification with atheromatous plaque and significant 
stenosis has led to the use of calcium scoring, where low-dose, non-contrast CT is 
used to identify coronary calcium deposition and to infer the likelihood of CAD. This 
has been examined specifically for the assessment of ischaemic cardiomyopathy
 [59]
. 
Cardiac CT 
[60]
 can discriminate between ischaemic and non-ischaemic causes 
in patients with a dilated phenotype. The gross morphology is non-specific, with 
ventricular dilatation and dysfunction, myocardial thinning and less commonly, 
intramyocardial fat. 
Delayed enhancement can be identified in a similar manner to late gadolinium 
enhancement with CMR. The presence of scar adds additional accuracy to the 
diagnosis of ischaemic cardiomyopathy
 [61]
. The identification of post-infarction scar 
is facilitated by the tissue differentiation between myocardium and fat. Following 
infarction, fatty replacement of the myocardium occurs, initially within fibrous scar 
but eventually leading to significant lipomatous metaplasia. On CT, fat in infarcted 
myocardium is usually, although not exclusively, subendocardially distributed in a 
curvilinear pattern, within a coronary artery territory 
[62]
. It is easily visualized, even 
on non-enhanced images undertaken for calcium scoring, and extremely common. 
Dilated cardiomyopathy 
The role of cardiac CT (CCT) is in excluding obstructive coronary artery 
disease. Other characteristic findings of DCM on CCT include increased diastolic LV 
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internal diameter measurement greater than 5.6 cm (upper limits of normal) 
[49]
. CCT 
also plays a role in determining DCM prognosis, based on ejection fraction (<35% for 
symptomatic patients and <30% for asymptomatic patients). 
 
Hypertrophic cardiomyopathy 
CCT may demonstrate basal myocardial hypertrophy with a small outflow 
tract, and an enlarged and elongated mitral valve. The associated haemodynamic 
obstruction may also demonstrate systolic anterior motion of the mitral valve leaflets 
and mid-systolic contact with the ventricular septum with either subaortic obstruction 
or mitral regurgitation. Differentials include hypertensive cardiomyopathy however 
HCM is usually non-concentric and asymmetric. 
 
Fig 3.11Cardiac CT - Hypertensive cardiomyopathy with concentric LV 
hypertrophy 
 
Restrictive cardiomyopathy 
CCT can identify similar values attained by echocardiography - LV cavity size 
and systolic function, biatrial enlargement, with abnormal diastolic function. 
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Arrhythmogenic right ventricular cardiomyopathy 
Cardiac CT is limited compared to CMRI. However, the detection of 
morphologic and wall motion abnormalities is favourable in patients with implantable 
defibrillators in situ. Findings that can assist include dilatation of the right ventricle 
and bulging/scalloped appearance of the RV wall. 
Fibrofatty replacement of the myocardium is well recognized as a feature of 
arrhythmogenic right ventricular cardiomyopathy (ARVC). Involvement of the left 
heart has been comprehensively described in arrhythmogenic right ventricular 
cardiomyopathy particularly in advanced disease. Initially, structural and 
morphological changes are limited to the ‗triangle of dysplasia‘ [63], comprising the 
RV outflow tract, the inferior RV wall, and the apex.  
The diagnostic criteria for ARVC include ECG and clinical parameters, 45 but 
imaging appearances predominate. While the Task Force Criteria do not consider CT, 
some of the morphological features are readily apparent and additional indicators have 
also been proposed. RV dilatation with scalloping of the free wall, and fat deposition 
in conspicuous trabeculae and the moderator have been described as being suggestive 
of ARVC on CT. 
Furthermore, the right ventricle often appears drastically thinned, due to 
fibrofatty replacement. LV involvement can also be assessed and has been described 
most often as wedge-shaped myocardial defects in the free wall.  
 
Myocarditis 
 
10% of severe viral myocarditis cases result in DCM. Echocardiography is 
useful to exclude causes of DCM and symptomatic heart failure (i.e. ischaemia, 
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valvular) from myocarditis. Chamber dilation, regional hypertrophy and ventricular 
remodelling are abnormalities regularly seen in myocarditis 
[64]
. 
MRI 
Cardiac MRI is indicated for evaluating a wide variety of congenital and 
acquired heart diseases, including cardiac masses, myocardial ischemia or infraction, 
cardiomyopathies, valvular disease, coronary artery disease, pericardial disease, and 
complex congenital anomalies 
[65]
. The high soft-tissue contrast, availability of a large 
FOV, multiplanar acquisition capability, and lack of ionizing radiation are particularly 
appealing features of cardiac MRI. Cardiac magnetic resonance (CMR) imaging has 
emerged as the gold standard for the assessment of myocardial pathology. However, 
the main limitation of cardiac MRI compared with CT is the evaluation of coronary 
calcifications.  
General contraindications for cardiac MRI include iron particles in the globe 
and intracranial aneurysm clips 
[65]
. Although also traditionally contraindicated for 
MRI because of concerns of arrhythmia and excess device heating, most patients with 
modern pacemakers and other types of implanted cardiac devices can safely undergo 
cardiac MRI examination at 1.5 T provided that appropriate precautions have been 
implemented 
[66]
. Pregnancy is considered a relative contraindication for cardiac MRI, 
although there are no known risks to the fetus. Except certain early models, valvular 
prostheses do not preclude cardiac MRI but their presence can degrade image quality 
[65]
. 
There are certain technical challenges unique to cardiac MRI. Most notably is 
the rapid and complex motion of the heart and pulsatility of the great vessels due to 
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normal contractility. In addition, the effects of respiratory motion and systolic 
ventricular blood velocities up to 200 cm/s further complicate cardiac imaging. 
Nevertheless, these issues are generally mitigated by implementation of ECG 
(cardiac) gating; navigator echo respiratory gating; breath-hold techniques; rapid, 
high-performance gradients; improved field homogeneity; and advanced pulse 
sequences. ECG gating can be either prospective or retrospective. 
Pulse Sequences 
Pulse sequences are software programs that encode the magnitude and timing 
of the radiofrequency pulses emitted by the MR scanner, switching of the magnetic 
field gradient, and data acquisition. The components of a pulse sequence are termed 
―imaging engines‖ and ―modifiers‖ [67]. Imaging engines are integral features of a 
pulse sequence, whereas modifiers are optional additions. 
Imaging engines include fast spin-echo (FSE), gradient-echo (GRE), steady-
state free precession (SSFP), echo-planar imaging (EPI), and single-shot versus 
segmented modes. Modifiers include fat suppression, inversion prepulse, saturation 
prepulse, velocity- encoded, and parallel imaging 
[67]
. 
Dark Blood Imaging 
Dark blood imaging refers to the low-signal- intensity appearance of fast-
flowing blood and is mainly used to delineate anatomic structures. Traditionally, spin-
echo (SE) sequences have been used for dark blood imaging. SE has been supplanted 
by the newer FSE and turbo spin-echo (TSE) techniques in cardiac imaging.  
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Bright Blood Imaging 
Bright blood imaging describes the high signal intensity of fast-flowing blood 
and is typically used to evaluate cardiac function. The main pulse sequences used for 
bright blood imaging include GRE (i.e., spoiled gradient recall [SPGR], turbo 
FLASH, turbo field echo, and fast-field echo [FFE]) and the technique termed 
―steady-state free precession‖ or ―SSFP.‖ EPI is another rapid sequence that is often 
used for functional assessment in cases in which arrhythmia precludes adequate 
gating. 
Modifiers 
Inversion recovery (IR) consists of applying additional 180° pulses. Double or 
triple IR can be used to further null signal from blood for black blood imaging, thereby 
improving contrast between the cardiac tissues and blood pool. This sequence is 
particularly useful for tumor imaging, delayed enhancement imaging, and coronary 
angiography. Fat suppression is accomplished in a similar manner, in which the 
inversion time of the additional selective 180° pulse is set to match the null time of fat. 
Saturation-recover preparatory pulses also improve T1-weighted imaging. It 
consists of applying a 90° flip angle and is less subject to signal intensity variations 
than IR techniques. The saturation- recover pulse is often used in combination with 
GRE and hybrid GRE-EPI pulse sequences for perfusion-weighted imaging and 
myocardial tagging. Tagging involves labelling the myocardium with a low-signal-
intensity grid. This enables quantification of myocardial strain and assessment of 
pericardial constriction. Tagging is also a more accurate method of assessing infarct-
related dysfunction than wall thickness analysis 
[68]
.  
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Phase-contrast imaging with velocity-encoded imaging is a noncontrast 
technique that is frequently used to estimate pulmonary blood flow (Qp) and systemic 
blood flow (Qs) to calculate the pulmonary-to-systemic flow ratio (Qp:Qs) to 
determine shunt fraction. A Qp:Qs > 1.5 usually indicates a significant left to- right 
shunt that requires surgical or percutaneous correction.  
Velocity-encoded imaging can also be used to calculate regurgitant fractions 
and valve area using the continuity equation. This technique is usually implemented 
via GRE pulse sequences. The gradient strength must be selected to match the 
expected velocities. A velocity setting that is too low can cause aliasing, whereas a 
setting that is too high results in noisy, inaccurate measurements. 
Parallel imaging techniques such as sensitivity- encoding (SENSE) and 
simultaneous acquisition of spatial harmonics (SMASH) enable accelerated imaging 
acquisition with short breath-hold times 
[65]
. These techniques make use of multiple 
coil arrays and sample limited portions of k-space over time. 
Contrast-Enhanced Techniques and Other Applications of Pulse Sequences 
The use of contrast material is an integral part of a myocardial viability study. 
Evaluation of myocardial viability with MRI is based on the phenomenon of delayed 
enhancement. This procedure consists of performing IR-GRE approximately 10 
minutes after injection of a gadolinium-based contrast medium.  Areas of myocardial 
infarct characteristically display enhancement when imaging is performed at an 
inversion time at which signal in the myocardium is maximally nulled. Dynamic 
perfusion imaging is also useful for characterizing myocardial viability and is often 
carried out via EPI. For tumor imaging, T1-weighted IR-FSE pulse sequences are 
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typically performed immediately after gadolinium injection. Contrast-enhanced MRI 
can also be used for evaluating the coronary arteries and great vessels. Maximum 
intensity projections (MIPs) and 3D vessel surface render renderings are particularly 
useful adjuncts. Alternatively, ECG-gated balanced SSFP without arterial spin 
labelling can be applied as an unenhanced angiographic technique for imaging the 
aorta as well as the coronary arteries. Arterial spin labelling can be further 
implemented to eliminate signal from venous flow
 [69]
.  
 
Fig 3.12 Transverse aortic phase-contrast images of a normal subject (Left) Two-
chamber delayed enhancement view (Right) shows transmural infarct in the 
anterior wall, apex, and inferoapex in distribution of LAD 
 
 
Fig 3.13 Contrast-enhanced cardiac MRI oblique sagittal view of a normal 
person 
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Traditional Fibrosis detection by Cardiac MR imaging 
Cardiac MR imaging has relied primarily on a qualitative characterization of 
the myocardium through visual analysis of characteristic enhancement patterns on late 
gadolinium-enhanced (LGE) MR images. By using a T1-weighted inversion recovery 
sequence (to null normal myocardium), after gadolinium administration, the signal 
difference between normal myocardium and focal fibrosis can be identified. Areas of 
fibrosis demonstrate greater gadolinium accumulation which is represented as a region 
of high intensity signal with a shorter T1 time than adjacent normal tissue
 [13]
. 
 
Fig 3.14 Late gadolinium-enhanced (LGE) MR images: Global subendocardial 
LGE in Amyloidosis (Left), Midwall LGE in Dilated cardiomyopathy (Right) 
 
 
Fig 3.15 Transmural LGE in Ischemic cardiomyopathy (Left), Patchy LGE in 
Hypertrophic cardiomyopathy 
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The main limitations of traditional LGE MR images are the identification and 
characterization of enhancement patterns is subjective, susceptible to inter- and 
intraobserver variations and that diffuse fibrosis may go undetected, as normal 
myocardium is needed as a standard of reference to contrast with a pattern of 
enhancement. To surpass these limitations, new tissue characterization strategies have 
been proposed, including the so-called T1 and T2 mapping technique. 
T1 Mapping technique 
T1 mapping refers to parametric maps that are generated from a series of 
images acquired with different T1 weighting so that each pixel can be assigned a T1 
value. T1 maps can be displayed using colour or threshold scales to enable 
quantitative and visual interpretation. Measured myocardial T1 values are influenced 
by physiological and technical factors, such as temperature, age, sex, heart rate, field 
strength and the pulse sequence used. 
Multiple CMR T1-based techniques have been employed for quantification of 
diffuse fibrosis (SASHA, SAPHIRE, etc.). Different T1 mapping sequences possess 
varying sensitivities to motion artifacts, heart rate, and intrinsic T1 values ranges. 
Therefore it is important to take it into consideration when comparing results between 
different studies. The most assessed T1 mapping sequence has been described by 
Messroghli et al. and is the MOLLI sequence (modified Look Locker inversion 
recovery). This technique was designed to overcome the limitations of motion and 
prolonged acquisition time
 [13]
. 
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T1 Mapping - MOLLI: sequence description 
T1 mapping is performed using ECG triggered Look-Locker Inversion Recovery 
(MOLLI).Three sets of Look-Locker (LL) acquisitions are performed successively with 
increasing inversion times (TI) within one breath hold. Images are acquired with a 
specific trigger delay (TD) to select end-diastole in consecutive heartbeats.  
The groups of images results in a set of 11 source images (traditional MOLLI 
protocol), which only differ in their inversion time order. By merging these raw 
images into one data set, T1 values can be computed for every pixel with three-
parameter curve fitting; a map of T1 in the imaging section can then be generated 
from these pixel values. 
T1 maps can be obtained any time before or after gadolinium contrast 
administration. Native T1 distinguishes normal from abnormal myocardium, reflecting 
myocardial disease involving the myocyte and interstitium
 [13]
.  
 
Fig 3.16 Series of images at various inversion times are performed successively, 
from which a T1 recovery curve is derived. The result is a T1 map that displays 
the T1 relaxation values pixel by pixel. 
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NATIVE (noncontrast) T1 MAP 
All tissues exhibit a characteristic range of normal T1 relaxation times 
(longitudinal or spin-lattice) that are based on a composite of their cellular and 
interstitial components (10). A region of interest (ROI) is placed on the myocardium 
(4-chamber view or short axis), ensuring that the ROI does not include blood or 
epicardial fat. The resulting pixel by pixel colour T1 maps are displayed using a 
customized table (0-2000ms) where normal myocardium is purple and increasing T1 
ranges from yellow to orange. 
Native myocardial T1 relaxation times vary by magnetic field strength (1.5 
vrs.3-T units), equipment manufacturer, and the type of mapping sequence used. 
Native T1 reflects myocardial disease involving the myocyte and the interstitium. A 
prolonged native myocardial T1 signal is encountered in various disease states that 
result in edema or fibrosis, and in amyloid deposition. Shortening of the native T1 
relaxation time can be seen with siderosis, Anderson-Fabry disease, and fat 
deposition. In addition, native T1 does not need to exclude patients with severe renal 
dysfunction or pregnancy
 [13]
.  
 
Fig 3.17 Native T1 mapping in a normal person 
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Contrast-enhanced T1 Mapping 
The use of gadolinium-based contrast agents shortens the native T1 relaxation 
time of myocardium. Areas with a disproportionate accumulation of contrast material 
(fibrosis) will therefore exhibit shorter T1 relaxation times. However, isolated 
postcontrast T1 values are influenced by a number of factors, including native T1, the 
type and dosage of gadolinium contrast used, and the postcontrast acquisition time 
within the contrast pharmacodynamics redistribution process. The latter depends on 
numerous systemic variables, such as body fat percentage, hematocrit levels, and 
glomerular filtration rate
 [13]
. 
Extracellular Volume (ECV) measurement 
Nonenhanced and contrast-enhanced T1 mapping allows evaluation of the 
proportion of gadolinium-based contrast agent in the blood pool versus in the 
myocardium. In conjunction with the hematocrit value, mapping enables 
quantification of the proportion of extracellular (interstitium and extracellular matrix) 
myocardial volume to cellular (myocyte) volume. An increased ECV is a marker of 
myocardial remodelling and is most often due to excessive collagen deposition (in the 
absence of amyloid or edema), which culminates in mechanical, electrical and 
vasomotor dysfunction. The ECV may be estimated from the concentration of 
extracellular contrast agent in the myocardium relative to the blood in a dynamic 
steady state .ECV can be calculated using a specific formula. The reported range of 
the ECV in healthy subjects is 21%-27%
 [36]
. 
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Clinical applications 
The presence of fibrosis has been shown to be an independent risk factor for 
overall mortality and the possible need for cardiac transplantation 
[6]
. Quantifying the 
degree of fibrosis may guide treatment with regard to revascularization, device 
implantation, and medical therapy. 
Mapping can also noninvasively represent a "sample" of tissue from the entire 
myocardium and can supplement or potentially replace invasive transvenous 
myocardial biopsy. Further, it may help identify the most appropriate location for 
biopsy, if biopsy is deemed clinically necessary
 [13]
. 
T1 mapping has the potential to be a useful technique for quantification of 
diffuse myocardial fibrosis in a variety of clinical settings, such as hypertrophic 
cardiomyopathy, dilated cardiomyopathy, amyloidosis and acute myocardial infarction. 
T2 MAPPING 
T2W magnetic resonance imaging pulse sequences have been used to detect 
oedema in patients with acute myocardial infarction, differentiate acute from chronic 
infarction, and identify acute myocarditis. The T2 mapping technique can accurately 
and reliably detect areas of myocardial oedema without the limitations of qualitative 
T2W imaging. T2 mapping sequences are useful for the detection of myocardial 
oedema due to acute myocardial infarction, myocarditis, stress cardiomyopathy, 
sarcoidosis, and cardiac allograft rejection 
[69]
. T2 mapping is considered superior 
compared with standard CMR parameters, global myocardial T1 mapping, and ECV 
for assessing the activity of myocarditis inpatients with recent-onset heart failure and 
reduced left ventricular function. Furthermore, T2 mapping was proven to be a novel 
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non-invasive tool for transplant monitoring, and initial findings support its potential 
role in rejection detection
 [69]
. 
However, T2W sequences have various problems including (a) signal intensity 
variability caused by phased array coils, (b) high signal from slow-moving ventricular 
blood that can mimic and mask elevated T2 in subendocardium, (c) motion artefacts, 
and (d) the subjective nature of T2W image interpretation. 
Limitations of T1 and T2 Mapping 
T1 and T2 mapping offer quantitative assessment of changes in tissue 
composition. However, one of the major obstacles for their clinical use is the variation 
in native T1 and T2 values related to imaging equipment and sequence. Further 
investigation is needed to establish ―normal normal‖ reference ranges for native T1 
and T2 relaxation values because there is great variation among manufacturers, 
magnetic field strengths, and clinical parameters. 
These reference values are required to distinguish various disease conditions 
from normal myocardium, especially in cases of diffuse disease. Knowledge of the 
properties of specific MR scanners is necessary for the clinical application of these 
techniques. 
Furthermore, the full clinical utility of T1 and T2 mapping is yet unknown 
because many diseases have not been adequately studied. There are still pending 
questions about (a) the potential replacement of LGE by native T1 mapping in the 
assessment of fibrosis, (b) whether native T1 mapping is more useful than T2 mapping 
in the evaluation of myocardial infarction, or whether they are complementary, and (c) 
how ECV can influence the clinical management of patients with heart disease
 [69]
. 
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HYPERTROPHIC CARDIOMYOPATHY 
Traditional cardiac MR imaging plays a valuable role in the analysis of 
ventricular morphology and function, with contrast-enhanced studies revealing patchy 
delayed enhancement in areas of hypertrophy. However, carriers of the mutation may 
have increased diffuse myocardial fibrosis without showing any other phenotypic trait 
of the disease. In this population, T1-mapping techniques may be extremely helpful. 
In addition to its use in primary diagnosis, myocardial mapping may also be useful on 
the prognosis and stratification of risk for adverse events by providing a longitudinal 
quantitative follow up of the degree of fibrosis.  
 
Fig 3.18 T1 mapping in hypertrophic cardiomyopathy. Four chamber view (Left) 
Short-axis nonenhanced MOLLI T1 map demonstrates prolonged T1 values in 
the area of myocardial hypertrophy (Right) 
 
Fig 3.19 LGE MR image four-chamber and two-chamber view through the same 
plane shows patchy wall enhancement characteristic of hypertrophic 
cardiomyopathy 
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DILATED CARDIOMYOPATHY 
By detecting the pattern of fibrosis, LGE contributes significantly to ruling out 
ischemic etiology (excluding subendocardial enhancement) in cases of dilated 
cardiomyopathy. Cardiac mapping can quantify the degree of myocardial T1 
abnormality and thus the degree of underlying fibrosis, which may have diagnostic 
and prognostic value
 [13]
.  
 
Fig 3.20 T1 mapping in nonischemic dilated cardiomyopathy. Four-chamber 
nonenhanced T1 map shows elevated diffuse T1 values (Left). Four-chamber 
LGE MR images show mesocardial enhancement. 
 
RESTRICTIVE CARDIOMYOPATHY - AMYLOIDOSIS 
The classic pattern on LGE T1-weighted MR images is global left ventricular 
subendocardial enhancement. Added features include left ventricular hypertrophy and 
abnormal diastolic function. In cases of diffuse myocardial involvement, the lack of a 
normal region of myocardium for comparison can make traditional cardiac MR 
images difficult to interpret. 
Noncontrast T1 mapping and myocardial ECV fraction are effective methods to 
noninvasively quantify cardiac amyloid burden and provide diagnostic information in 
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patients with suspected cardiac amyloidosis. An elevated myocardial T1 value reflects 
the severity of cardiac involvement and correlates well with markers of systolic and 
diastolic dysfunction
 [16]
. 
T1 mapping has also demonstrated to be effective in distinguishing subtypes of 
amyloidosis, as that T1 times in hereditary amyloidosis may not be as high as in the 
AL subtype. This differentiation is clinically relevant because treatment and prognosis 
vary by subtype
 [13]
.  
 
Fig 3.21 T1 mapping in amyloidosis. Nonenhanced four chamber MOLLI T1 
map shows diffusely increased T1 values (Left). Two chamber LGE MR image 
shows subendocardial enhancement (Right). 
 
MYOCARDITIS 
Cardiac MR imaging is the imaging tool of choice in diagnosing acute 
myocarditis. Subepicardial patchy or nodular LGE in conjunction with an underlying 
wall-motion abnormality is a classic finding during the first week; however, the 
enhancement pattern usually becomes diffuse within 7 days after infection. 
T1 mapping has shown higher sensitivity compared with T2-weighted and LGE 
MR imaging techniques alone, in the detection of acute myocarditis 
[13]
.  
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Fig 3.22 T1 mapping in myocarditis. Four-chamber nonenhanced MOLLI T1 
map shows prolonged focal areas of T1 relaxation times in the lateral wall (Left), 
corresponding to the epipericardial enhancement on four chamber LGE (Right). 
 
MYOCARDIAL INFARCTION 
Magnetic resonance (MR) imaging plays an important role in evaluating the 
various stages of MI. MR imaging is valuable in establishing a diagnosis of chronic 
MI and distinguishing this condition from nonischemic cardiomyopathies, mainly 
through use of delayed-enhancement patterns. MR imaging also provides clinicians 
with several prognostic indicators that enable risk stratification, such as scar burden, 
microvascular obstruction, hemorrhage, and peri-infarct ischemia. The extent and 
transmurality of scar burden have been shown to have independent and incremental 
prognostic power over a range of left ventricular function. The extent of scarring at 
MR imaging is an important predictor of successful outcome after revascularization 
procedures, and extensive scarring in the lateral wall indicates poor outcome after 
cardiac resynchronization therapy. Scar size at MR imaging is also a useful surrogate 
end point in clinical trials. Finally, MR imaging can be used to detect complications of 
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MI, such as aneurysms, pericarditis, ventricular septal defect, thrombus, and mitral 
regurgitation.  
 
Fig 3.23 MR imaging findings in acute MI. Two-chamber T2-weighted STIR 
image shows high-signal-intensity myocardial edema in the mid and apical 
anterior wall (Left). Two-chamber delayed-enhancement image shows 
subendocardial scarring in the mid to apical anterior wall (Right) 
 
ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA 
CMRI black blood spin echo (SE) images will show fibrofatty replacement of 
the RV free walls (fat saturation will enhance this accuracy). However, recently black 
blood imaging is thought to be less sensitive in diagnosis of ARVC compared to 
demonstration of RV systolic and diastolic dysfunction. Thus, cine imaging with a 
quantitative measure of increased RV volumes (end-diastolic volume >150 mL, end-
systolic volume >70 mL indexed to body surface area) is also diagnostic. 
Apart from the above volume and functional abnormalities, other morphologic 
irregularities in tissue characterization that may occur in ARVC include focal wall 
thinning (<2 mm), wall hypertrophy (>6 mm), moderator band hypertrophy, and 
trabeculae thickening. 
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LGE can demonstrate scarring of the RV wall. However, it should be noted that 
infiltration of the RV free wall also occurs in elderly and obese patients as well as 
long-term steroid users. In addition, LGE of the RV myocardium is also present in 
cardiac sarcoidosis and chronic right-sided myocarditis. Thus, it is imperative that 
diagnosis of ARVC should not be based solely on CMRI findings
 [44]
. 
 
Fig 3.24 Arrhythmogenic right ventricular cardiomyopathy Long-axis four-
chamber steady state free precession cine MRI image demonstrating the 
characteristic irregular contour of the right ventricular free wall 
 
PREVIOUS STUDIES ON MYOCARDIAL T1 AND T2 MAPPING: 
A review of the literature revealed some articles which studied myocardial T1 
and T2 mapping in evaluation of myocardial diseases. 
Dabir et al
[70]
,who used a 3 T scanner (Ingenia, Philips Healthcare, Best, The 
Netherlands) and Modified Look- Locker inversion recovery for T1 mapping reported 
mean native T1 value of 1052 ± 23ms in healthy controls. 
Dass et al
[71]
, who used a Siemens 3T Trio MR system (Siemens Healthcare 
Erlangen, Germany) and shortened MOLLI for T1 mapping reported a mean native T1 
value of 1178±13 ms in normal control patients. The study also reported that mean T1 
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relaxation time was increased in HCM and DCM (HCM 1209±28 ms, DCM 1225±42 
ms, normal 1178±13 ms, P<0.05) and T1 values correlated with disease severity.  
Puntmann et al.
[72]
, who used MOLLI sequence for T1 mapping in a 3-T 
scanner (Achieva TX, Philips Healthcare, Best, the Netherlands) reported a mean 
native T1 value of 1,070±55ms for subjects with healthy hearts. They also reported 
that native T1 value was significantly longer in patients with cardiomyopathy (HCM 
1,254±43ms, NIDCM 1,239±57ms) compared with control subjects (1,070±55ms) (p 
< 0.01) and that native T1 could differentiate between healthy and diseased 
myocardium with high diagnostic accuracy.  
Lurz et al.
[73]
, who also performed T1 mapping with a modified Look-Locker 
inversion recovery sequence in a 3-T scanner (Verio, Siemens Healthcare, Erlangen, 
Germany) reported mean native T1 value of 1,159±62ms for subjects with healthy 
hearts and that values for native T1 were significantly higher in patients with acute 
myocarditis (1,203±71ms) than in patients with no myocarditis. 
Leutkens et al
[74]
 reported mean native T1 value of 1089.1±44.9ms in control 
subjects using 3-T MR imaging system (Ingenia 3T; Philips Healthcare, Best, the 
Netherlands) andMOLLI for T1 mapping. They observed that native T1 relaxation 
times were significantly longer in patients with acute myocarditis than in control 
subjects (1185.3±49.3 vs 1089.1±44.9, respectively; P < .001).  
Hinojar et al
[75]
 reported a mean native T1 value of 1,045±23ms in subjects 
with healthy hearts using a 3.0-T scanner (Achieva, Philips Healthcare, Best, the 
Netherlands). This study reported mean native T1 value of 1,189±52ms in acute 
myocarditis and that native T1 was superior to T2-weighted imaging and late 
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gadolinium enhancement with high diagnostic accuracy and positive and negative 
predictive values to distinguish health and disease.  
Toussaint et al.
[76]
, who used a 3 Tesla scanner (Magnetom Trio Tim; Siemens 
AG Healthcare Sector, Erlangen, Germany) and MOLLI sequence for myocardial T1 
was determined reported mean native T1 value of 1155.3±63.9ms in subjects with 
healthy hearts and a mean T1 relaxation time of 1179.2±48.3ms in myocarditis cases. 
Boomen et al.
[77]
, in their systematic review and meta-analysis of native T1 
reference values for nonischemic cardiomyopathies reported a weighted mean T1 value 
of 1081±45 msec in controls at 3T. Their systematic review and meta-analysis concluded 
that native T1 mapping can potentially assess myocardial changes in HCM, DCM, MC 
compared to controls. They reported a mean T1 value of 1166±55 msec in HCM patients 
and 1193±60 msec for DCM patients. The mean T1 value in acute MC patients was 
1193±60 msec. The metaanalysis showed a significant increase of the myocardial T1 
values for HCM, DCM patients and acute MC patients compared with controls. 
Dall’Armellina E et al[78] reported a mean T1 value of 1257±97 ms in 
infarcted myocardium normal (n=10) 1166±60ms 
von Knobelsdorff-Brenkenhoff F et al
[79] 
reported normal myocardial T2 
value of 45.1 ms at 3T [77] . 
Spieker et al
[80]
 reported that T2 values were significantly increased in acute 
myocarditis (68.1 ± 5.8ms) compared to controls (60.0 ± 4.2ms) and decreased over 
time. Patients with clinical recovery revealed significantly decreased T2 relaxation 
times at follow-up examinations; however, T2 values were still elevated compared to 
healthy controls. 
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4. AIM OF THE STUDY 
 
OBJECTIVES 
 
1. To identify normal baseline T1 and T2 values of myocardium in 3T MRI using 
Myomaps 
 
2. To assess the value of native T1 and T2 relaxation times in various diffuse 
myocardial diseases 
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5 MATERIALS AND METHODS 
 
5.1 Study Area  :   Barnard Institute of Radiology, Madras Medical 
  College, Chennai. 
5.2 Study Period  : 12 months (June 2017 – May 2018) 
5.3 Sample Size  : 52 
5.4 Study Design  : Prospective study  
5.5 Inclusion criteria:  
CASES: Subjects with established myocardial disease and cardiac magnetic 
resonance finding suggestive of the same 
CONTROLS: Healthy volunteers who were nonsmokers, had no history of cardiac 
disease, comorbidities, had a normal ECG and ECHO were taken as controls after 
obtaining informed consent                       
5.6 Exclusion criteria: 
Patients with orthopnea, claustrophobia, MRI non-compatible devices 
5.7 METHODOLOGY 
 
This prospective study was performed after obtaining clearance from our 
Institutional Ethics Committee and institutional informed consent guidelines were 
observed.  
5.7.1 Study Population: 
Between June 2017 and July 2018, 38 unselected consecutive subjects (19 
female, 19 male) referred for CMR were primarily included in this study. The patients 
were screened using the drawn inclusion/ exclusion criteria. Assignment to the above 
mentioned diagnoses was performed by experienced cardiologists in consensus using 
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all available clinical information (medical history, ECG, laboratory tests and 
echocardiography). Diagnosis of myocarditis, DCM, HCM, and RCM was made in 
accordance to established diagnostic criteria. 
12 healthy volunteers who were nonsmokers, had no history of cardiac disease, 
hypertension, family history of cardiomyopathy or sudden death, had a normal 12-lead 
ECG and ECHO and no other comorbidities were taken as controls after obtaining 
informed consent. All patients were required to provide written informed consent 
before study participation. 
 
5.7.2 MRI Examination: 
All MRI studies were done on a 3-Tesla MRI system (MAGNETOM Skyra, 
Siemens Healthineers, Erlangen, Germany).Coil used was phased array 18 channel 
body coil. 
MRI PROTOCOL 
 
A standardized cardiac MR protocol was used which included the following 
sequences: 
1. T2 HASTE axial 
2. True FISP CINE images – four chamber view, two chamber view and short axis 
views 
3. T2 STIR axial in selected cases 
4. Native T1 and T2 mapping  
5. PSIR post contrast images in selected cases 
Retrospective ECG gating was used for Cine True FISP images and 
prospective ECG gating for other sequences. 
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For cine imaging steady-state free precession (SSFP) images were acquired in 
standard long and short axis views (TR 39ms, TE 1.4ms, matrix 139 x 208, field of 
view 420 x 380 mm2, flip angle 57°, bandwidth 962 Hz/pixel, slice thickness 6 mm). 
 Native T1 and T2 mapping was performed using Siemens Myomap protocol in 
short axis slices through the apex, mid-body and base. The average native myocardial 
T1and T2 values were obtained from region of interest (ROI) drawn in the anterior, 
septal, inferior and posterolateral walls in each of these slices. 
The parameters for native T1 are as follows: 
1. For RR interval >700ms, TR  280ms, TE 1.12 ms, matrix 256 x 144, field 
of view 360 x 306 mm
2
, flip angle 35°, bandwidth 1085 Hz/pixel, slice 
thickness 8 mm;  
2. For RR interval <700ms, TR 272ms, TE 1.2ms, matrix 195 x 132, field of 
view 360 x 307 mm2, flip angle 35°, bandwidth 1085 Hz/pixel, slice 
thickness 5 mm) 
The parameters for native T2 are TR  207ms, TE 1.32ms, matrix 192 x 116, field of 
view 360 x 288 mm
2
, flip angle 12°, bandwidth 1184 Hz/pixel, slice thickness 8 mm;  
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MYOCARDIAL MAPPING FORMAT 
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CASE 1 – NORMAL CONTROL 
 
History: Normal control 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG 5.14 True FISP four chamber (top left), short axis midbody (top right) and two 
chamber (bottom)  
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FIG 5.11 Native T1 map four chamber view (top left), short axis mid body (top right) 
native T2 map four chamber view (bottom left) and short axis mid body (bottom right) 
 
 LV WALL 
ANTERIOR SEPTUM INFERIOR LATERAL 
T1(ms) 1150 1191 1041 1133 
T2(ms) 34.7 41 33.8 37.3 
 
Normal mean native T1 and T2 values 
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CASE 2 - ASYMMETRIC SEPTAL HYPERTROPHIC TYPE OF 
CARDIOMYOPATHY 
 
History: 16 year old male patient presented with worsening dyspnoea on exertion. 
ECHO showed LV hypertrophy involving the interventricular septum. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG 5.1 White blood imaging four chamber (top left), short axis midbody (top right) 
and two chamber (bottom) shows asymmetrical hypertrophy of interventricular 
septum 
 
s 
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SDF 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG 5.2 Native T1 map four chamber view (top left), short axis mid body (top right) 
and native T2 map short axis midbody (bottom) 
 
 LV WALL 
ANTERIOR SEPTUM INFERIOR LATERAL 
T1(ms) 1319.8 1389 1265 1275.7 
T2(ms) 39 48.8 37.8 36.5 
 
There is increased native T1 values in LV wall especially in the septal wall and 
increased native T2 value in septal wall 
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CASE 3 - HYPERTROPHIC CARDIOMYOPATHY CONCENTRIC TYPE 
 
History: 9 year old female patient presented with moderate dyspnoea on exertion. 
ECHO showed hypertrophy of LV walls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG 5.3 White blood imaging four chamber (top left), short axis midbody (top right) 
and two chamber (bottom) shows concentric hypertrophy of left ventricle  
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FIG 5.4 Native T1 map four chamber view (top left), short axis mid body (top right) 
native T2 map four chamber view (bottom left) and short axis mid body (bottom 
right). 
 
 LV WALL 
ANTERIOR SEPTUM INFERIOR LATERAL 
T1(ms) 1448 1437 1412 1492 
T2(ms) 49.6 47.2 44.2 53.2 
 
There is significantly increased native T1 and T2 values in anterior, septal, inferior 
and lateral LV walls 
 
 66 
CASE 4 - DILATED CARDIOMYOPATHY 
 
History: 19 year old male patient presented with breathlessness and pedal edema since 
childhood. ECHO showed dilated left atrium and left ventricle. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG 5.5 White blood imaging four chamber (top left), short axis midbody (top right) 
and two chamber (bottom) shows mildly dilated left atrium and significantly dilated 
left ventricle 
 
 
LA 
LV 
LV 
LV 
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FIG 5.6 Native T1 map four chamber view (top left), short axis mid body (top right) 
native T2 map four chamber view (bottom left) and short axis mid body (bottom right) 
 
 LV WALL 
ANTERIOR SEPTUM INFERIOR LATERAL 
T1(ms) 1339 1367 1344 1377 
T2(ms) 40.7 40.5 41.55 39.9 
 
There is increased native T1 values in anterior, septal, inferior and lateral LV walls. 
No significantly increased native T2 values. 
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CASE 5 – RESTRICTIVE CARDIOMYOPATHY (AMYLOIDOSIS) 
History: 55 year old male patient presented with shortness of breath. Fatigue and 
palpitations for past 4 months.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG 5.5 T2 HASTE axial (top left), True FISP four chamber (top right) and short axis 
midbody (bottom) shows mildly dilated left atrium, significantly dilated left ventricle, 
bilateral pleural effusions, minimal pericardial effusion and diffuse mild patchy 
delayed upper enhancement. 
 
 
 
LA 
LV 
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FIG 5.8 Native T1 map four chamber view (top left), short axis mid body (top right) 
native T2 map four chamber view (bottom left) and short axis mid body (bottom right) 
 
 LV WALL 
ANTERIOR SEPTUM INFERIOR LATERAL 
T1(ms) 1351 1362 1354 1448 
T2(ms) 35.3 40.6 40.4 39.5 
 
There is significantly increased native T1 values in anterior, septal, inferior and lateral 
LV walls. No significantly increased native T2 values. 
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CASE 6 - RESTRICTIVE CARDIOMYOPATHY (ENDOMYOCARDIAL 
FIBROSIS) 
 
History: 55 year old male patient presented with dyspnoea and pedal edema.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG 5.9 True FISP four chamber (top left), post contrast late gadolinium enhancement 
images (top right) and short axis midbody (bottom) shows apical soft tissue thickening 
in right ventricle apex with subendocardial delayed hyperenhancement, non enhancing 
thrombus attached to right atrial free wall, dilated right atrium and right ventricle, 
bilateral pleural effusions and moderate pericardial effusion 
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FIG 5.10 Native T1 map four chamber view (top left), short axis mid body (top right) 
native T2 map short axis mid body (bottom) 
 
 LV WALL 
ANTERIOR SEPTUM INFERIOR LATERAL 
T1(ms) 1553 1467 1379 1483 
T2(ms) 36.6 39.8 42.2 38.2 
 
There is significantly increased native T1 values in anterior, septal, inferior and lateral 
LV walls. No significantly increased native T2 values. 
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CASE 7 – MYOCARDIAL INFARCTION 
History: 52 year old male patient known case of coronary artery disease, planned for 
coronary bypass surgery came for myocardial viability assessment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG 5.10 True FISP four chamber (top left), post contrast late gadolinium 
enhancement four chamber view (top right), short axis midbody (bottom left) and two 
chamber (bottom right) shows delayed myocardial hyperenhancement in the anterior 
,anteroseptal and inferoseptal walls of left ventricle 
. 
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FIG 5.11 Native T1 map four chamber view (top left), short axis mid body (top right) 
native T2 map four chamber view (bottom left) and short axis mid body (bottom right) 
 
 LV WALL 
ANTERIOR SEPTUM INFERIOR LATERAL 
T1(ms) 1212 1566.5 1176 1190 
T2(ms) 38.7 47 36.9 43.3 
 
Native T1 and T2 values are significantly increased in the septum. 
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CASE 8 - MYOCARDITIS 
History: 40 year old female patient presented with fever, arrhythmia (recurrent 
ventricular tachycardia) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG 5.12 STIR axial (top left), PSIR post contrast images four chamber view (top 
right) and short axis midbody (bottom) shows patchy STIR hyperintensity in LV wall 
and patchy mid myocardial enhancement in the anteroseptal and inferoseptal walls of 
left ventricle 
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FIG 5.11 Native T1 map four chamber view (top left), short axis mid body (top right) 
native T2 map four chamber view (bottom left) and short axis mid body (bottom right) 
 
 LV WALL 
ANTERIOR SEPTUM INFERIOR LATERAL 
T1(ms) 1372 1424 1398 1336 
T2(ms) 45.9 45.1 43.4 45.3 
 
There is significantly increased native T1 and T2 values in anterior, septal, inferior 
and lateral LV walls 
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6. STATISTICAL ANALYSIS 
 
 
PLANNING OF STATISTICAL ANALYSIS 
 
 
The collected data were analysed with IBM.SPSS statistics software 
23.0Version. 
To describe about the data descriptive statistics frequency analysis, percentage 
analysis were used for categorical variables and the mean & S.D were used for 
continuous variables. 
To find the significant difference in the multivariate analysis the one way 
ANOVA with Tukey's Post-Hoc test was used. 
To find the significance in categorical data Chi-Square test was used. 
In all the above statistical tools the probability value .05 is considered as 
significant level. 
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7. OBSERVATION & RESULTS 
 
7.1 AGE RANGE DISTRIBUTION 
 
 
Table 7.1 TABLE SHOWING AGE WISE DISTRIBUTION OF CONTROLS 
 
AGE GROUP FREQUENCY PERCENT 
UPTO 25 YRS 3 25 
26-35 YRS 2 16.6 
36-45 YRS 2 16.6 
46-55 YRS 5 41.6 
TOTAL 12 100 
 
 
 
FIG 7.1.1 BAR CHART SHOWING AGE DISTRIBUTION OF CONTROLS 
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Table 7.1.2 TABLE SHOWING AGE WISE DISTRIBUTION OF CASES 
AGE GROUP FREQUENCY PERCENT 
UPTO 25 YRS 4 10 
26-35 YRS 6 15 
36-45 YRS 14 35 
46-55 YRS 13 32.5 
56-65 YRS 3 7.5 
TOTAL 40 100 
 
 
FIG 7.1.2 BAR CHART SHOWING AGE DISTRIBUTION OF CASES 
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7.2  GENDER DISTRIBUTION 
 
Table 7.2 TABLE SHOWING GENDER DISTRIBUTION AMONG STUDY 
GROUP 
 
 FEMALES MALES 
CONTROLS 4 8 
CASES 19 21 
TOTAL 23 29 
 
 
FIG 7.2 BAR CHART SHOWING GENDER DISTRIBUTION AMONG 
STUDY GROUP 
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7.3  FREQUENCY DISTRIBUTION AMONG CASES 
 
Table 7.3 TABLE SHOWING FREQUENCY DISTRIBUTION AMONG 
CASES 
GROUPS FEMALES MALES TOTAL PERCENT 
Hypertrophic cardiomyopathy 5 3 8 20 
Dilated cardiomyopathy 4 3 7 17.5 
Restrictive cardiomyopathy 2 4 6 15 
ARV 2 4 6 15 
Myocarditis 4 1 5 12.5 
Myocardial infraction 2 6 8 20 
Total 19 21 40 100 
 
FIG 7.3 BAR CHART SHOWING FREQUENCY DISTRIBUTION AMONG 
CASES 
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7.4 NATIVE T1 VALUES AMONG STUDY GROUP 
 
Table 7.3 TABLE SHOWING NATIVE T1 VALUES AMONG STUDY GROUP 
Groups N Mean Std. 
Deviation 
95% Confidence 
Interval for Mean 
Minimum Maximum 
Lower 
Bound 
Upper 
Bound 
Hypertrophic 
cardiomyopathy 
8 1355.86 44.67 1318.52 1393.20 1308.42 1415.17 
Dilated 
cardiomyopathy 
7 1341.31 41.48 1302.94 1379.67 1266.25 1388.75 
Restrictive 
cardiomyopathy 
6 1370.37 97.75 1267.79 1472.95 1276.47 1472.25 
ARVD 6 1289.48 49.68 1237.34 1341.61 1223.52 1348.67 
Myocarditis 5 1418.68 8.62 1407.98 1429.39 1404.58 1428.17 
Myocardial 
infraction 
8 1316.26 48.20 1275.96 1356.56 1256.00 1398.17 
Normal 12 1186.47 45.67 1157.45 1215.49 1108.83 1261.92 
Total 52 1308.77 90.14 1283.68 1333.87 1108.83 1472.25 
 
 
FIG 7.3 BAR CHART SHOWING NATIVE T1 VALUES AMONG STUDY 
GROUP 
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7.4 NATIVE T2 VALUES AMONG STUDY GROUP 
 
Table 7.4 TABLE SHOWING NATIVE T2 VALUES AMONG STUDY GROUP 
Groups N Mean Std. 
Deviation 
95% Confidence 
Interval for Mean 
Minimum Maximum 
Lower 
Bound 
Upper 
Bound 
Hypertrophic 
cardiomyopathy 
8 42.11 2.38 40.13 44.10 39.17 44.75 
Dilated 
cardiomyopathy 
7 40.64 1.62 39.14 42.14 37.83 43.25 
Restrictive 
cardiomyopathy 
6 41.46 3.06 38.24 44.67 35.58 43.75 
ARVD 6 41.43 3.45 37.81 45.05 38.25 47.25 
Myocarditis 5 44.37 0.63 43.58 45.15 43.58 45.08 
Myocardial 
infraction 
8 40.16 2.52 38.05 42.26 36.75 44.83 
Normal 12 38.25 1.49 37.30 39.20 35.08 40.17 
Total 52 40.79 2.79 40.01 41.56 35.08 47.25 
 
 
FIG 7.4 BAR CHART SHOWING NATIVE T2 VALUES AMONG STUDY 
GROUP 
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7.4  COMPARISON OF NATIVE T1 VALUES BETWEEN CONTROLS AND 
CASES  
 
Table 7.4TABLE SHOWING COMPARISON OF NATIVE T1 VALUES 
BETWEEN CONTROLS AND CASES 
Dependent Variable Mean 
Difference (I-J) 
Std. 
Error 
Sig. 95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
N
o
rm
a
l 
Hypertrophic 
cardiomyopathy 
-169.38715
*
 23.95166 .000 -243.2897 -95.4846 
Dilated 
cardiomyopathy 
-154.83373
*
 24.95706 .000 -231.8384 -77.8290 
Restrictive 
cardiomyopathy 
-183.89722
*
 26.23773 .000 -264.8534 -102.9410 
ARVD -103.00278
*
 26.23773 .005 -183.9590 -22.0466 
Myocarditis -232.21111
*
 27.93220 .000 -318.3956 -146.0267 
Myocardial 
infraction 
-129.78819
*
 23.95166 .000 -203.6907 -55.8856 
 
7.5  COMPARISON OF NATIVE T2 VALUES BETWEEN CONTROLS AND 
CASES  
 
Table 7.4TABLE SHOWING COMPARISON OF NATIVE T2 VALUES 
BETWEEN CONTROLS AND CASES 
Dependent Variable Mean 
Difference (I-J) 
Std. 
Error 
Sig. 95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
N
o
rm
a
l 
Hypertrophic 
cardiomyopathy 
-3.86458
*
 1.03693 .009 -7.0640 -.6652 
Dilated 
cardiomyopathy 
-2.39286 1.08046 .308 -5.7266 .9409 
Restrictive 
cardiomyopathy 
-3.20833 1.13590 .093 -6.7131 .2965 
ARVD -3.18056 1.13590 .098 -6.6854 .3242 
Myocarditis -6.11667
*
 1.20926 .000 -9.8478 -2.3855 
Myocardial 
infraction 
-1.90625 1.03693 .530 -5.1057 1.2932 
 
 84 
RESULTS 
 
Among 52 subjects studied, 29 were males and 23 were females, i.e., 55.8% 
were males and 44.2% were females. 
 
The study group consisted of 8 cases (15.4%) of Hypertrophic cardiomyopathy, 
7 cases (13.5%) of Dilated cardiomyopathy, 6 cases (11.5%) of Restrictive 
cardiomyopathy, 6 cases (11.5%) of arrhythmogenic right ventricular dysplasia, 5 
cases (9.6%) of myocarditis, 8 cases (15.4%) of myocardial infarction and 12 controls 
(23.1%). 
 
Mean native T1 and T2 values for controls, hypertrophic cardiomyopathy, 
dilated cardiomyopathy, restrictive cardiomyopathy, arrhythmogenic right ventricular 
dysplasia, myocarditis and myocardial infarction are summarized in the tables and bar 
charts above. The comparison among mean native T1 and T2 values of normal 
controls and cases with myocardial disease showed the following results: 
1. The native T1 values for the healthy control group on our 3T MRI system was 
1186.47±45.67ms.  
2. The average native myocardial T1 value ranged in the group of subjects with 
healthy hearts between 1108.83 and 1261.91 ms 
3. The average native T1 value ranged in the joint analysis of all patients with diffuse 
diseased myocardium between 1266.25 and 1428.16 ms. 
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4. The mean T1 value of the groups HCM was 1355.86±44.67ms, DCM was 
1341.31±41.48ms, RCM was 1370.37±90.14ms, ARVD was 1289.48±49.68ms, 
acute myocarditis was 1418.68±8.62ms and myocardial infarction was 
1316.26±48.20ms.  
5. The highest T1 values were observed in the myocarditis group (1418.68±8.62ms) 
and the lowest T1 values were observed in the ARVD group (1289.48±49.68ms). 
6. The mean T1 values of the groups HCM (1355.86±44.67ms, p<0.05), DCM 
(1341.31±41.48ms, p<0.05), RCM (1370.37±90.14ms. p<0.05), ARVD 
(1289.48±49.68ms, p<0.05), acute myocarditis (1418.68±8.62ms, p<0.05) and 
myocardial infarction (1316.26±48.20ms, p<0.05) were significantly higher than 
that of the healthy control group.   
7. Thus the average native T1 value in cardiac MR imaging can be useful in 
differentiating between healthy and diffuse myocardial disease groups. 
8. The native T2 values for the healthy control group on our 3T MRI system was 
38.25±1.49ms.  
9. The average native myocardial T2 value ranged in the group of subjects with 
healthy hearts between 35.08 and 40.17ms 
10. The average native T2 value ranged in the joint analysis of all patients with diffuse 
diseased myocardium between 35.58 and 47.25ms. 
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11. The mean T2 value of the groups HCM was 42.11±2.38ms, DCM was 
40.64±1.62ms, RCM was 41.46±3.06ms, ARVD was 41.43±3.45ms, acute 
myocarditis was 44.37±0.63ms and myocardial infarction was 40.16±2.52ms.  
12. The highest T2 values were observed in the myocarditis group (44.37±0.63ms)and 
the lowest T2 values were observed in the myocardial infarction group 
(40.16±2.52ms). 
13. The mean T2 values of the groups HCM (42.11±2.38ms, p<0.05) and acute 
myocarditis (44.37±0.63ms, p<0.05) were significantly higher than that of the 
healthy control group. 
14. There was no statistically significant difference in mean T2 values between the 
groups DCM (40.64±1.62ms, p=0.3), RCM (41.46±3.06ms, p=0.09), ARVD 
(41.43ms, p=0.09), myocardial infarction (40.16±0.63ms, p=0.53) and healthy 
control group.  
15. Thus the average native T2 value in cardiac MR imaging can be useful in 
differentiating between healthy and groups with HCM and myocarditis. 
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8.  DISCUSSION 
Myocardial fibrosis is a fundamental process in the development of myocardial 
dysfunction in majority of myocardial pathologies, leading to poor outcomes. It is an 
independent risk factor for overall mortality. Early identification of this underlying 
process is important for diagnosis and essential for further management. 
Endomyocardial biopsy was the only available method for assessment of 
myocardial fibrosis. But due to risk of serious complications and sampling error 
associated with this technique, it was hence seldom performed.  
With advancements in cardiac magnetic resonance imaging (CMR), several 
novel techniques for the detection and characterization of myocardial pathologies 
were developed. Cardiac MR has become a standard investigation for the evaluation 
of several cardiac pathologies. Cardiac MR imaging primarily relied on qualitative 
characterization of the myocardium and detecting focal myocardial fibrosis through 
visual analysis of characteristic enhancement patterns on late gadolinium-enhanced 
(LGE) MR images. However, myocardial signal intensity in diffuse myocardial 
fibrosis may be nearly isointense and thus be ―nulled‖ appearing like normal tissue. 
Moreover as LGE involves intravenous administration of gadolinium-based contrast 
agents, it is contraindicated in those with renal failure. Novel techniques, including 
native T1 and T2 mapping which directly quantifies signal from the myocardium, 
have been developed to surpass these limitations in the detection of diffuse myocardial 
diseases. Thus mapping techniques may supplement or potentially replace invasive 
myocardial biopsy. Moreover, as gadolinium is not used in this technique, it can be 
used in patients with renal dysfunction.  
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In addition to myocardial fibrosis, native T1 measurement can also detect 
excess of water as in oedema 
[14, 15]
, protein deposition 
[16, 17]
, and lipid 
[13, 14]
 or iron 
(haemorrhage, siderosis) 
[20]
. The changes of myocardial native T1 mapping reflect 
cardiac diseases, such as acute coronary syndromes, infarction, myocarditis, and 
diffuse fibrosis (that present with high T1) 
[21]
, and systemic diseases, such as cardiac 
amyloid (high T1) 
[21]
 Anderson-Fabry disease (low T1)
 [22]
, and siderosis (low T1).  
The T2 mapping technique can accurately and reliably detect areas of myocardial 
oedema in conditions like acute myocardial infarction 
[23]
, myocarditis 
[24, 25]
, and 
cardiac allograft rejection.  
In our study, out of 52 subjects, 29 (55.8%) were males and 23 (44.2%) were 
females. The study group consisted of 8 cases (15.4%) of Hypertrophic 
cardiomyopathy, 7 cases (13.5%) of Dilated cardiomyopathy, 6 cases (11.5%) of 
Restrictive cardiomyopathy, 6 cases (11.5%) of arrhythmogenic right ventricular 
dysplasia, 5 cases (9.6%) of myocarditis, 8 cases (15.4%) of myocardial infarction and 
12 controls (23.1%).The age and gender distribution of myocardial diseases and their 
frequency distribution were almost similar to previous studies in literature. 
Our study aimed to identify normal baseline T1 and T2 values of myocardium 
in 3T MR and to assess the value of native T1 and T2 relaxation in the differentiation 
between healthy and diseased myocardium. In our study, native T1 and T2 mapping 
was performed using Siemens Myomap protocol in short axis slices through the apex, 
mid-body and base. The average native myocardial T1 and T2 values for controls, 
hypertrophic cardiomyopathy, dilated cardiomyopathy, restrictive cardiomyopathy, 
arrhythmogenic right ventricular dysplasia, myocarditis and myocardial infarction 
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were obtained from region of interest (ROI) drawn in the anterior, septal, inferior and 
posterolateral walls in each of these slices.  
Native T1 and T2 relaxation times are genuine tissue parameters at a given 
field strength. However they are affected by the type of sequence used, sequence 
parameters and by the MR system. 
NATIVE T1 MAPPING  
A mean native T1 value of 1052 ± 23ms in healthy controls was reported 
Dabir et al
[70]
,who used a 3T scanner (Ingenia, Philips Healthcare, Best, The 
Netherlands) and Modified Look- Locker inversion recovery for T1 mapping. 
Dass et al
[71]
, who used a Siemens 3T Trio MR system (Siemens Healthcare 
Erlangen, Germany) and shortened MOLLI for T1 mapping reported a mean native T1 
value of 1178±13 ms in normal control patients. The study also reported that mean T1 
relaxation time was increased in HCM and DCM (HCM 1209±28 ms, DCM 1225±42 
ms, normal 1178±13 ms, P<0.05) and T1 values correlated with disease severity.  
Puntmann et al 
[72]
, who used MOLLI sequence for T1 mapping in a 3-T 
scanner (Achieva TX, Philips Healthcare, Best, the Netherlands) reported a mean 
native T1 value of 1,070±55ms for subjects with healthy hearts. They also reported 
that native T1 value was significantly longer in patients with cardiomyopathy (HCM 
1,254±43ms, NIDCM 1,239±57ms) compared with control subjects (1,070±55ms) (p 
< 0.01) and that native T1 could differentiate between healthy and diseased 
myocardium with high diagnostic accuracy.  
Lurz et al.
[73]
, who also performed T1 mapping with a modified Look-Locker 
inversion recovery sequence in a 3-T scanner (Verio, Siemens Healthcare, Erlangen, 
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Germany) reported mean native T1 value of 1,159±62ms for subjects with healthy 
hearts and that values for native T1 were significantly higher in patients with acute 
myocarditis (1,203±71ms) than in patients with no myocarditis. 
Leutkens et al
[74]
 reported mean native T1 value of 1089.1±44.9ms in control 
subjects using 3-T MR imaging system (Ingenia 3T; Philips Healthcare, Best, the 
Netherlands) and MOLLI for T1 mapping. They observed that native T1 relaxation 
times were significantly longer in patients with acute myocarditis than in control 
subjects (1185.3±49.3 vs 1089.1±44.9, respectively; P < .001).  
Hinojar et al
[75]
 reported a mean native T1 value of 1,045±23ms in subjects 
with healthy hearts using a 3.0-T scanner (Achieva, Philips Healthcare, Best, the 
Netherlands). This study reported mean native T1 value of 1,189±52ms in acute 
myocarditis and that native T1 was superior to T2-weighted imaging and late 
gadolinium enhancement with high diagnostic accuracy and positive and negative 
predictive values to distinguish health and disease.  
Toussaint et al.
[76]
, who used a 3 Tesla scanner (Magnetom Trio Tim; Siemens 
AG Healthcare Sector, Erlangen, Germany) and MOLLI sequence for myocardial T1 
was determined reported mean native T1 value of 1155.3±63.9ms in subjects with 
healthy hearts and a mean T1 relaxation time of 1179.2±48.3ms in myocarditis cases. 
Boomen et al.
[77]
, in their systematic review and meta-analysis of native T1 
reference values for nonischemic cardiomyopathies reported a weighted mean T1 
value of 1081±45 msec in controls at 3T. Their systematic review and meta-analysis 
concluded that native T1 mapping can potentially assess myocardial changes in HCM, 
DCM, MC compared to controls. They reported a mean T1 value of 1166±55 msec in 
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HCM patients and 1193±60 msec for DCM patients. The mean T1 value in acute MC 
patients was 1193±60 msec. The metaanalysis showed a significant increase of the 
myocardial T1 values for HCM, DCM patients and acute MC patients compared with 
controls. 
Dall’Armellina E et al[78] reported a mean T1 value of 1257±97 ms in 
infarcted myocardium normal (n=10) 1166±60ms 
The mean native T1 values for the healthy control group on our 3T MRI system 
was 1186.47±45.67ms. This was comparable to the mean native T1 values reported by 
Dass et al
[71] 
(1178±13 ms) and Lurz et al
[73]
 (1,159±62ms). The average native 
myocardial T1 value ranged in the group of subjects with healthy hearts between 
1108.83 and 1261.91 ms. The average native T1 value ranged in the joint analysis of 
all patients with diffuse diseased myocardium between 1266.25 and 1428.16 ms. 
The mean T1 value of the groups HCM was 1355.86±44.67ms, DCM was 
1341.31±41.48ms, RCM was 1370.37±90.14ms, ARVD was 1289.48±49.68ms, acute 
myocarditis was 1418.68±8.62ms and myocardial infarction was 1316.26±48.20ms. 
These values were slightly higher than mean T1 values reported by above mentioned 
studies. This might reflect the differences in the type of sequence used, sequence 
parameters and by the MR system. The highest T1 values were observed in the 
myocarditis group. 
The mean T1 values of the groups HCM (1355.86±44.67ms, p<0.05), DCM 
(1341.31±41.48ms, p<0.05), RCM (1370.37±90.14ms. p<0.05), ARVD 
(1289.48±49.68ms, p<0.05), acute myocarditis (1418.68±8.62ms, p<0.05) and 
myocardial infarction (1316.26±48.20ms, p<0.05) were significantly higher than that 
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of the healthy control group. Thus the average native T1 value in cardiac MR imaging 
can be useful in differentiating between healthy and diffuse myocardial disease 
groups. 
NATIVE T2 MAPPING  
von Knobelsdorff-Brenkenhoff F et al
[79] 
reported normal myocardial T2 
value of 45.1 ms at 3T [77] . 
Spieker et al
[80] 
reported that T2 values were significantly increased in acute 
myocarditis compared to controls and decreased over time. Patients with clinical 
recovery revealed significantly decreased T2 relaxation times at follow-up 
examinations; however, T2 values were still elevated compared to healthy controls. 
The native T2 values for the healthy control group on our 3T MRI system was 
38.25±1.49ms. This was slightly lower than reported by previous studies. The average 
native myocardial T2 value ranged in the group of subjects with healthy hearts 
between 35.08 and 40.17ms. The average native T2 value ranged in the joint analysis 
of all patients with diffuse diseased myocardium between 35.58 and 47.25ms. 
The mean T2 value of the groups HCM was 42.11±2.38ms, DCM was 
40.64±1.62ms, RCM was 41.46±3.06ms, ARVD was 41.43±3.45ms, acute 
myocarditis was 44.37±0.63ms and myocardial infarction was 40.16±2.52ms. The 
highest T2 values were observed in the myocarditis group. Our mean T2 values in 
acute myocarditis were comparable with previous studies. Only a limited degree of 
comparison of our data with previous studies is possible with regards to T2 values in 
groups HCM, DCM, RCM and ARVD as sufficient studies on 3T MR system have 
not been published in literature in these disease groups.  
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The mean T2 values of the groups HCM (42.11±2.38ms, p<0.05) and acute 
myocarditis (44.37±0.63ms, p<0.05) were significantly higher than that of the healthy 
control group. There was no statistically significant difference in mean T2 values 
between the groups DCM (40.64±1.62ms, p=0.3), RCM (41.46±3.06ms, p=0.09), 
ARVD (41.43ms, p=0.09), myocardial infarction (40.16±0.63ms, p=0.53) and healthy 
control group. Thus the average native T2 value in cardiac MR imaging can be useful 
in differentiating between healthy and groups with HCM and myocarditis. 
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9. LIMITATION OF THE STUDY 
 
The number of patients in some subgroups of myocardial pathologies is rather 
small. Hence further studies on larger cohorts are required. 
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10. CONCLUSION 
Cardiac MR is a non-invasive, quantifiable, and feasible technique which 
allows the evaluation of myocardial diseases. 
This study, despite some limitations, showed the feasibility of native T1 and T2 
mapping in discriminating between healthy and diseased myocardium, which can aid 
in further management. Significant differences in native T1 and T2 values between 
normal controls and various groups of cases with myocardial pathologies were 
apparent in this study. This data may justify the more routine use of this technique in 
the characterisation, assessment and follow-up of myocardial diseases. 
Other potential benefits include the ability of this technique in identifying 
diffuse or early myocardial pathologies which may be missed on traditional CMR 
method ssuch as late gadolinium enhancement (LGE) imaging. Moreover as native 
myocardial mapping does not involve intravenous administration of gadolinium-based 
contrast agents, it can be used in those with renal failure as opposed to late gadolinium 
enhancement (LGE) imaging which is contraindicated in this group of people. 
Myocardial mapping technique may also possibly help in avoiding unnecessary 
myocardial biopsies in certain cases of myocardial diseases. Further, it may help 
identify the most appropriate location for biopsy, if it is deemed clinically necessary. 
CMR with the LGE imaging method is the gold standard for non-invasive 
myocardial tissue characterization and scar imaging/quantification. T1 and T2 
mapping takes this forward to the measurement of diffuse processes in a quantitative 
pixel-by-pixel approach. It is one of the most rapidly developing and evolving fields 
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in CMR. Recent advances in acquisition sequences have made it possible for short 
acquisition times, improved accuracy and precision, and robust reproducibility 
without the need for contrast material. Its clinical applications extend from rare 
diseases such as Fabry disease to more frequent ones like cardiac amyloidosis to 
conditions encountered in everyday clinical practice like myocardial infarction.  
 Quantitative T1maps enhance the ability of CMR to characterize the 
myocardium by allowing depiction of diffuse myocardial fibrosis. Consequently, 
native T1 mapping might supply a CMR biomarker for myocardial fibrosis, justifying 
their use in clinical practice. However, more research and multicenter studies are 
required before a large-scale application in clinical decision-making. More effort 
towards setting reference ranges for the different pathologies that alter T1and T2 
values, standardization of the acquisition techniques and creating differentiating 
algorithms for their overlapping values are required. 
To conclude, native T1 and T2 mapping techniques can be readily incorporated 
into the existing cardiac MR protocols, and their combined use may provide important 
knowledge into fundamental disease processes affecting the myocardium that can 
otherwise be difficult to detect. This will further our understanding of pathological 
mechanisms in the myocardium and lead to early detection, better diagnostic path-
ways, improved prognostication, and improved monitoring of therapy. 
Our study has assessed native T1 and T2 values in 3T SIEMENS SKYRA 
system, which yielded comparable results to other SIEMENS systems. Native T1 and 
T2 mapping can be a potential biomarker in the prognostication and follow up of 
various diffuse myocardial diseases like myocarditis and cardiomyopathies. 
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 7 
ABBREVIATIONS 
ECM                    -          Extracellular Matrix  
CMR/CMRI         -          Cardiac magnetic resonance imaging  
LGE                      -          Late gadolinium enhancement  
MRI                      -          Magnetic resonance imaging 
RCA                      -          Right coronary artery  
PDA                      -          Posterior descending artery  
LAD                      -         Left anterior descending  
HCM                     -          Hypertrophic cardiomyopathy  
LVOT                    -          Left ventricular outflow tract  
DCM                     -          Dilated cardiomyopathy  
RCM                     -           Restrictive cardiomyopathy  
MI                         -           Myocardial infarction  
NSTEMI               -           Non–ST-segment elevation myocardial infarction  
ARVD                   -          Arrhythmogenic right ventricular dysplasia  
LV                         -          Left ventricle  
RV                         -          Right ventricle  
RVOT                    -          Right ventricular outflow tract  
 8 
CT                         -           Computed tomography  
CAD                      -          Coronary artery disease  
CCT                       -           Cardiac Computed tomography  
ARVC                    -           Arrhythmogenic right ventricular cardiomyopathy  
FSE                        -           Fast spin-echo  
GRE                       -           Gradient-echo  
SSFP                      -           Steady-state free precession  
EPI                         -           Echo-planar imaging  
SE                          -            Spin-echo  
TSE                        -            Turbo spin-echo  
SPGR                     -            Spoiled gradient recall  
FFE                        -            Fast-field echo  
IR                           -            Inversion recovery  
SENSE                   -            Sensitivity- encoding  
SMASH                 -             Simultaneous acquisition of spatial harmonics  
MIP                        -             Maximum intensity projections  
MOLLI                  -             Modified Look Locker inversion recovery 
TD                         -              Trigger delay  
 9 
ECV                      -                Extracellular Volume  
ROI                       -                Region of interest  
HASTE                 -                Half Fourier single shot turbo spin echo 
FISP                      -                Fast imaging with steady state free precession 
STIR                      -                Short tau inversion recovery 
PSIR                      -                Phase sensitive inversion recovery 
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PATIENT PROFORMA  
 
STUDY TITLE: 
“MYOCARDIAL MAPPING IN EVALUATION OF MYOCARDIAL 
DISEASES AND ASSESSING NORMATIVE VALUES IN CONTROLS” 
 
Sl. No: 
Name: 
Age/Sex: 
Occupation: 
Address: 
 
Presenting Complaints and History: 
 
 
ECG Findings: 
 
 
ECHO Findings: 
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DATA COLLECTION PROFORMA: 
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PATIENT INFORMATION SHEET 
 
“MYOCARDIAL MAPPING IN EVALUATION OF 
MYOCARDIAL DISEASES AND ASSESSING NORMATIVE 
VALUES IN CONTROLS’’ 
 
 
 Your cooperation would be valuable to us for the same 
 The privacy of patients in the research will be maintained throughout the 
study. In the event of any publication or presentation resulting from the 
research, no personally identifiable information will be shared. 
 Taking part of the study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time. Your decision will not 
result in any loss of benefits to which you are otherwise entitled. 
 The result of the special study may be intimated to you at the end of the 
study period or during the study if anything is found abnormal which may 
aid in the management or treatment. 
 
 
 
 
 
 
Signature of the investigator                    Signature of participant 
Dr. VIMAL CHACKO MONDY 
Date: 
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PATIENT CONSENT FORM 
 
STUDY TITLE: 
“MYOCARDIAL MAPPING IN EVALUATION OF MYOCARDIAL 
DISEASES AND ASSESSING NORMATIVE VALUES IN CONTROLS’’ 
        
PARTICIPANT’S NAME:  
AGE:                       SEX:                    IP.NO. : 
 
  I confirm that I have understood the purpose of procedure for the above 
study. I have the opportunity to ask the questions and all my questions and 
doubts have been answered to my satisfaction. 
 I have been explained about the pitfall in the procedure. I have been 
explained about the safety, advantage and disadvantage of the technique.  
I understand that my participation in the study is voluntary and that I’m 
free to withdraw at any time without giving any reason. 
 I understand that investigator, regulatory authorities and the ethics 
committee will not need my permission to look at my health records both in 
respect to current study and any further research that may be conducted in 
relation to it, even if I withdraw from the study. 
I understand that my identity will not be revealed in any information 
released to third parties or published, unless as required under the law. I agree 
not to restrict the use of any data or results that arise from the study. 
I HEREBY CONSENT TO UNDERGO COMPLETE PHYSICAL 
EXAMINATION, BIOCHEMICAL AND RADIOLOGICAL 
INVESTIGATION PERTAINING TO THE STUDY. 
 
 
 
Signature/Thumb Impression of 
Participant 
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 îƒèÀ¬ìò ðƒèOŠ¹‹ æˆ¶¬öŠ¹‹ Ýó£Œ„C ï¡º¬øJ™ 
ªõŸP ªðø ªðK¶‹ àîMò£è Ü¬ñ»‹. 
 
cƒèÀ‹ Þ‰î Ýó£Œ„CJ™ ðƒ«èŸè ï£ƒèœ M¼‹¹A«ø£‹. 
Þ‰î Ýó£Œ„CJ™ àƒèÀ‚° ðK«ê£î¬ùèœ ªêŒ¶ Üî¡ 
îèõ™è¬÷ Ýó£Œ«õ£‹ Üîù£™ îƒè÷¶ «ï£J¡ ÝŒõP‚¬è«ò£ 
Ü™ô¶ CA„¬ê«ò£ ð£FŠ¹ ãŸðì£¶ â¡ð¬î»‹ ªîKMˆ¶ 
ªè£œA«ø£‹.  
 
º®¾è¬÷ Ü™ô¶ è¼ˆ¶è¬÷ ªõOJ´‹«ð£«î£ Ü™ô¶ 
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1 DHAKSHANAMOORTHY 16 M HCM 1319.8 1389 1265 1275.7 39 48.8 37.8 36.5 
2 ANANDHI 34 F Myocarditis 1423 1485 1416 1372 43.1 46.9 43.1 40.9 
3 RAVIKUMAR 59 M DCM 1289 1332 1321 1390 42.2 43 41.5 41 
4 SATHISH 49 M RCM 1430 1384 1361 1428 40.3 43.6 43.1 40.6 
5 GOVINDARAJ 65 M MI 1319 1141.5 1281 1192.5 41.6 31.7 44.3 38.6 
6 DHANUSHKODI 54 F DCM 1304 1409 1325.5 1326 32.9 44.9 40.9 38.4 
7 SUKUMAR 39 M RCM 1237 1230 1226 1243 39.4 41.8 45.2 43.1 
8 BABU 36 M ARVD 1251 1260 1257 1286 41.3 40.1 36.3 42.1 
9 SHANKARI 44 F NORMAL 1217 1177.2 1212.5 1230 41.4 38.5 33.2 42.1 
10 SUMITHRA 45 F NORMAL 1159 1180 1200 1134 40.6 38.2 36.8 41.1 
11 KUMUDHA 48 F HCM 1339 1300.5 1229.5 1281 39.3 38.8 34.7 42.5 
12 VELU 49 M MI 1339 1331 1237 1226 42.1 43.5 37.6 39.5 
13 SELVI 48 F RCM 1103 1343.5 1335 1258 30.1 39.4 28.2 29 
14 SARADHA 55 F DCM 1284 1290.7 1375.2 1432 42.7 45.8 45.4 42.9 
15 KARTHIK 38 M Myocarditis 1385 1472 1430 1417 41.5 42.6 43.1 43.5 
16 SENTHIL MURUGAN 38 M ARVD 1191 1247.5 1188.2 1329.7 39.3 35.9 34.5 45.7 
17 SENGAMMAL 51 F NORMAL 1124 1045 1110 1133 36.4 40.6 37.6 36.4 
18 POONGAVANAM 43 F ARVD 1320 1294 1345 1321 40.3 39.1 45.1 46.1 
19 VIJAYA LAKSHMI 48 F RCM 1242 1134 1158.6 1232.5 43.1 40.6 45.1 38.8 
20 DEVI 45 F DCM 1352 1387 1421 1365 36.5 48.1 40.6 43.2 
21 NANDHINI 30 F Myocarditis 1421 1458 1394 1427 43.1 40.9 42.7 45.1 
22 VEERAMA 48 F ARVD 1320 1310 1325 1334 41.6 38.4 40.5 41.8 
23 KALLIDASS 55 M NORMAL 1195.3 1171 1164 1176 39.1 41.3 38.2 41.4 
24 MANI 41 M HCM 1429 1432 1399 1457 47.2 46.1 42.7 48.9 
25 PAVENDIRAN 25 M NORMAL 1060.5 1143.5 1162 1066 40.6 38.4 32.8 43.6 
26 SELVAKUMAR 38 M HCM 1228 1284 1267 1301 45 41.6 46.2 44.3 
27 AKBAR BASHA 52 M MI 1212 1566.5 1176 1190 38.7 47 36.9 43.3 
28 KANNIYAPPAN 45 M ARVD 1349 1343 1361 1371 39.4 43.1 46.5 44.8 
29 SIVA SHANKAR 46 M MI 1323 1363 1216 1211.5 41.6 38.8 38.5 38.1 
30 AISHWARYA 26 F HCM 1321 1354 1253 1271 38.4 44.5 39.1 37.6 
31 SELVARAJ 34 M NORMAL 1150 1191 1041 1133 34.7 41 33.8 37.3 
32 SEENUMATHIRI 55 M RCM 1553 1467 1379 1483 36.6 39.8 42.2 38.2 
33 KISHORE 55 M RCM 1351 1362 1354 1448 35.3 40.6 40.4 39.5 
34 PADMA 45 F MI 1353 1466 1246 1230 42.8 42.5 38.6 37 
35 BANU 38 F HCM 1299 1325 1310 1294 41.9 41.6 38.5 41.1 
36 THULASIRAMAN 26 M NORMAL 1139 1158 1100.5 1181.5 39.9 35 34.1 35.4 
37 SEKAR 57 M MI 1459 1370 1473 1294 34.3 41.3 40.1 55.9 
38 SUMATHI 33 F Myocarditis 1410 1411 1413 1375 45.6 43.9 43.8 45.1 
39 PUNITHA 22 F HCM 1391 1410 1337 1386 43.6 46.1 45.1 45.3 
40 SHAKIL AHAMED 55 M NORMAL 1290 1255 1246 1171 34.9 33.8 32.9 34.2 
41 PERIYADURAI 14 M NORMAL 1271 1262 1234 1230 37.2 39.4 38.3 39.3 
42 MUNIYAN 46 M MI 1342 1362 1350 1283 38.1 35.2 36.1 33.2 
43 MALLIGA 55 F NORMAL 1070 1065 1126 1034 38.7 41 37.4 41.4 
44 MOHAMMED SUHAI 19 M DCM 1339 1367 1344 1377 40.7 40.5 41.55 39.9 
45 NANDHAKUMAR 40 M ARVD 1377 1301 1491 1392 37.4 41.6 50.2 55.7 
46 THANUJA 9 F HCM 1448 1437 1412 1492 49.6 47.2 44.2 53.2 
47 KARPAGAM 40 F DCM 1318 1340 1354 1369 41.2 42.1 43.5 41.6 
48 MURUGAN 51 M NORMAL 1149 1173 1206 1183 35.4 36.8 38.1 34.6 
49 PAVENDHAN 17 M DCM 1168 1237 1308 1186 33.9 35.6 32.3 38.8 
50 SHELLA 30 F MI 1277 1288 1249 1324 37.1 36.5 38.1 35.5 
51 SANTHOSH KUMAR 24 M NORMAL 1230.5 1221.67 1238 1261 34.9 38.9 39 42.9 
52 SASIKALA 40 F Myocarditis 1372 1424 1398 1336 45.9 45.1 43.4 45.3 
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